SUMMARY OF FINDINGS FOR THE MAIN COMPARISON *\[Explanation\]***PQ for reducing P. falciparum transmission with artemisinin-based treatmentsPatient or population:** People with symptomatic malaria**Settings:** Malaria-endemic areas**Intervention:** Single dose or short course PQ plus malaria treatment including an artemisinin derivative**Control:** Malaria treatment including an artemisinin derivative, without PQ**OutcomesIllustrative comparative risks\* (95% CI)Relative effect(95% CI)Number of participants(trials)Quality of the evidence(GRADE)Assumed riskCorresponding riskControlPQMalaria incidence, prevalence or EIR**\-\--0 trials-**People infectious to mosquitoes**\-\--0 trials-**Participants with gametocytes on microscopy or PCR**^1^ (day 8)**Dose \< 0.4 mg/kgRR 0.67** (0.44 to 1.02)223 (1 trial)⊕⊕⊕○ ^2,3,4^ **low34 per 10023 per 100** (15 to 35)**Dose 0.4 to 0.6 mg/kgRR 0.34** (0.19 to 0.59)269 (2 trials)⊕⊕⊕○ ^4,5,6^ **high32 per 10011 per 100** (6 to 19)**Dose = 0.6 mg/kgRR 0.29** (0.22 to 0.37)1380(7 trials^7^)⊕⊕⊕○**high** ^8,9^**30 per 1009 per 100** (7 to 11)**Mean percent change in haemoglobin**^10^The mean percent drop in Hb from baseline in the control group was15%The mean percent drop in Hb from baseline in the intervention groups was 3% lower(from 10% lower to 4% higher)101(1 trials)⊕○○○ **very low** ^10,11^\*The basis for the **assumed risk** (for example, the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).**PQ:** Primaquine; **CI:** Confidence interval; **RR:** Risk ratio.GRADE Working Group grades of evidence**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.**Very low quality:** We are very uncertain about the estimate.[^4][^5][^6][^7][^8][^9][^10][^11][^12][^13]

Background
==========

Malaria is a febrile illness due to infection with the plasmodium parasite, and is transmitted between humans via mosquitoes. Of the five plasmodium species known to cause illness in humans, *P. falciparum* is the most common, especially in sub-Saharan Africa, and causes the majority of severe illness and deaths. The clinical illness develops due to the presence of asexual stage parasites (sporozoites) in the persons bloodstream, but transmission to mosquitoes is via the sexual stage parasites (gametocytes), which develop from sporozoites at some point after infection.

Artemisinin-based combination therapies (ACTs) are currently recommended worldwide as the primary treatment for symptomatic *P. falciparum* malaria (WHO [@b116]). The artemisinin-derivatives treat the clinical illness by rapidly reducing the number of circulating sporozoites, which also reduces the potential for sporozoites to develop into gametocytes for onward transmission. The artemisinin-derivatives have been shown to kill early developing gametocytes, but they have no direct effects on mature gametocytes (Price [@b107]; Chotivanich [@b85]; Okell [@b104]; Okell [@b105]). The partner drugs in ACTs (mefloquine, amodiaquine, piperaquine, lumefantrine and sulfadoxine-pyrimethamine) are schizonticides with variable effects on gametocytes, and none adequately targets mature gametocytes (Drakeley [@b88]; Barnes [@b78]). In untreated infection, gametocytes can remain present for months as successive new generations are produced, and even following treatment they may persist for several weeks (Smalley [@b109]; Eichner [@b90]; Bousema [@b80]).

The mean circulation time of a mature *P. falciparum* gametocyte in humans has been estimated by microscopy or polymerase chain reaction (PCR) to be between 3.4 to 6.5 days (Smalley [@b109]; Eichner [@b90]; Bousema [@b80]). The minimum number of gametocytes required for transmission from an infected person to a mosquito has been estimated to be in the range of 100 to 300 per μL blood (Carter [@b84]), and the percentage of bites on humans that result in mosquito infection ranges between 0.3% and 46%, although most estimates are in the range of 1% to 10% (Graves [@b93]; Killeen [@b99]; Churcher [@b86]).

After uptake of a *P. falciparum-*infected blood-meal by the mosquito, gametocytes mature into male and female gametes. When fertilized, diploid oocysts develop on the mosquito\'s stomach wall and subsequently mature into sporozoites that migrate to the salivary glands, ready to be released when biting the next human. The median number of oocysts formed in wild caught infected mosquitoes is two to three (Rosenberg 2008). Each oocyst develops thousands of sporozoites, but only about 20% are thought to reach the mosquito salivary glands, and fewer than 25 sporozoites on average are ejected during mosquito blood-feeding (Rosenberg 1990; Rosenberg 2008).

Description of the intervention
-------------------------------

Primaquine (PQ) is the only drug in common use which is known to kill mature *P. falciparum* gametocytes (Burgess [@b24]; Pukrittayakamee [@b12]; Chotivanich [@b85]), and with the recent emphasis on malaria elimination, there has been a renewed interest and emerging literature on PQ\'s potential value in reducing malaria transmission (White [@b114]; WHO [@b118]; White [@b115]). PQ is an 8-aminoquinolone whose pharmacokinetic mode of action is not well understood, but it is known to be rapidly metabolized, with a half-life of six hours (White [@b112]). PQ does not directly affect the asexual stages of *P. falciparum* which cause the clinical illness (Arnold [@b77]; Pukrittayakamee [@b12]), and does not appear to affect the early or maturing gametocytes (Bhasin [@b79]; White [@b113]). Consequently, a combination of PQ and an artemisinin-derivative (as part of ACT) would target all stages of the gametocyte and have the greatest potential for reducing onward transmission to mosquitoes (White [@b115]; WHO [@b118]).

One of the constraints to widespread use of PQ is that the drug is known to cause haemolysis in people with glucose-6-phosphate dehydrogenase (G6PD) deficiency. The deficiency is X-linked and expression highly variable with a wide variety of variants and levels of G6PD deficit (Howes [@b96]). PQ is a haemolytic trigger, and can cause a haemolytic anaemia that occasionally is serious with haemoglobinaemia and renal failure. The effect depends on the degree of enzyme deficiency, the dose of PQ, and the pattern of the exposure. These occasional, but clearly serious, adverse effects have led to a reputation of being \"unsafe\" although little is known about haemolysis at low doses of PQ.

The WHO 2010 *Guidelines for the Treatment of Malaria* recommended adding a single dose of PQ at 0.75 mg/kg to treatment for uncomplicated *P. falciparum* malaria in people who are not G6PD deficient with the goal of reducing transmission at the community level (WHO [@b116]). However, since testing for G6PD deficiency was rarely done, and due to the concerns about the safety of this single dose, the WHO convened a special expert review group in 2012 to reconsider this recommendation (WHO [@b117]). The expert group concluded that 1) G6PD testing should be done more widely; 2) Countries already implementing single dose PQ should reduce the dose to 0.25 mg/kg in G6PD deficient patients; and 3) Countries not currently implementing single dose PQ but which are targeting malaria elimination, or are threatened by artemisinin resistance, should add 0.25 mg/kg PQ to treatment for uncomplicated *P. falciparum* malaria (White [@b114]; WHO [@b118]).

How the intervention might work
-------------------------------

A single dose of PQ could contribute to reducing malaria transmission through its effects on mature gametocytes, and it is reasonable to assume that reducing the density and duration of gametocytes in the blood of infected patients will reduce the duration of potential infectiousness to mosquitoes at the level of the individual (see Figure [1](#fig01){ref-type="fig"}). However, any subsequent effects on the number of mosquitoes infected (infectiousness), or the number of new malaria infections in the community (transmission) are impossible to predict without measuring these effects using reliable methods.

![Review logic framework: The potential points in the Plasmodium parasite life cycle that could be impacted by primaquine and the outcomes used to measure impact](CD008152-0001-f1){#fig01}

Infectiousness to mosquitoes can be measured directly by allowing mosquitoes to feed on infected individuals who have been treated with and without PQ (Killeen [@b99]; Bousema [@b82]), or estimated indirectly by measuring the infection rates of wild-caught mosquitoes (Graves [@b94]; Lines [@b101]).

Community level transmission can be measured through large cluster-randomized trials, or less reliably through controlled before and after studies. Within any community there are people who are carriers of *P. falciparum* gametocytes but who do not seek treatment (Bousema [@b81]). This is most apparent in areas of high endemicity, where much of the adult population has acquired immunity, and low level parasitemias do not produce symptoms. This reservoir of gametocytes in untreated adults will continue to facilitate community level transmission and may dilute any possible effect of PQ. Indeed, these dilutional effects may even be important in low transmission settings.

Recently, with the move toward a target of elimination, some policy makers are considering mass treatment strategies (von [@b111]; Sturrock [@b110]) to reduce transmission or contain outbreaks once transmission is reduced to low levels. In this instance, it seems more likely that a higher proportion of the population with gametocytes will be detected or treated, or both, and that this could be effective in reducing or interrupting transmission. This policy is being considered in countries with lower intensity transmission, on islands or at the northern and southern fringes of malaria distribution, or both (GMAP [@b92]; Mendis [@b103]). Effective antimalarial drugs are likely to play a large role in this new strategy. One question in this effort is whether there is a role for PQ given in addition to curative antimalarial drugs, including artemisinin combination therapies (ACTs), to further reduce the infection transmissibility (White [@b113]).

The transmission blocking potential of PQ has also been suggested as a strategy to reduce the spread of artemisinin resistant parasites in Southeast Asia (Breman [@b83]).

Why it is important to do this review
-------------------------------------

PQ could play a role in the next phase of *P. falciparum* malaria control, particularly malaria elimination and possibly eradication. Whether elimination or eradication can be accomplished, or at the very least, the efficiency with which PQ is deployed, depends on getting the details right on dose, timing and the situation in which it is used. Best use must be made of existing data and opportunities for filling in missing information (and not duplicating what already is known) should be created and moved on quickly. This review is intended to clarify what is and is not known, and to identify which missing pieces are critical to defining effective uses of PQ.

Objectives
==========

1\. To assess whether giving PQ or other 8AQ in addition to treatment for *P. falciparum* infection reduces:

-   malaria transmission intensity;

-   infectiousness of infected people to mosquitoes;

-   potential infectiousness (gametocyte prevalence and density over time).

2\. To compare the effects of different 8AQs.

3\. To determine whether the effects of PQ or other 8AQ differ if the primary treatment drug is artemisinin based or another antimalarial.

4\. To estimate the frequency of severe or haematological adverse events associated with single dose or short course PQ when it has been used for this purpose.

Methods
=======

Criteria for considering studies for this review
------------------------------------------------

### Types of studies

Randomized controlled trials (RCTs) or quasi-RCTs including individual- or cluster-RCTs. Cluster-RCTs must have had at least two clusters per arm.

### Types of participants

Adults or children with *P. falciparum* infection or a mixed infection of *P. falciparum* and other *Plasmodium* species. For individual RCTs, eligible studies must have diagnosed patients by blood slide, rapid diagnostic test, or other valid molecular method; for cluster-RCTs, diagnosis could have been by clinical judgment if that was standard in the trial area at the time of the trial.

### Types of interventions

#### Intervention

A single dose or short course (up to seven days) of PQ or other 8-aminoquinoline (8AQ) added to malaria treatment(s).

#### Control

Identical treatment for malaria not including PQ/8AQ (or substituting placebo for PQ/8AQ); or using a different 8AQ with same malaria treatment, or using different dose of PQ/8AQ with same malaria treatment(s).

### Types of outcome measures

#### Primary outcomes

Figure Figure [1](#fig01){ref-type="fig"} provides an outline of transmission of malaria that helps clarify these terms.

**a) Transmission**

-   Entomological inoculation rate

-   Malaria incidence

-   Malaria prevalence

**b) Infectiousness**

-   People who infect mosquitoes

-   Mosquitoes infected by direct feeding

**c) Potential infectiousness**

-   AUC of gametocyte density (y-axis) over time (x-axis)

-   Gametocyte prevalence (estimated by microscopy or PCR)

-   Gametocyte density (estimated by microscopy or PCR)

-   Gametocyte clearance time (duration of gametocyte carriage)

**Adverse events**

-   Serious adverse events leading to hospital admission or death

-   Haematologic effects

    1.  ∘ Haemolysis (higher prevalence)

    2.  ∘ Haemoglobin concentration (decline)

    3.  ∘ Packed cell volume (decline)

#### Secondary outcomes

-   Presence of asexual stage parasites (may be reported as treatment failure rate)

-   Asexual parasite clearance time (duration of asexual carriage)

Search methods for identification of studies
--------------------------------------------

We attempted to identify all relevant trials, regardless of language or publication status (published, unpublished, in press, and in progress).

The search strategy is in Appendix 1.

### Electronic searches

#### Databases

We searched the following databases up to 10 February 2014 using the search terms and strategy described in Appendix 1: the Cochrane Infectious Diseases Group Specialized Register; the Cochrane Central Register of Controlled Trials (CENTRAL), published in *The Cochrane Library* (Issue 2 2014); MEDLINE (1966 to 10 Feb 2014); EMBASE (1980 to 10 Feb 2014); and LILACS (1982 to 10 Feb 2014). Also, we checked the *meta*Register of Controlled Trials (*m*RCT) and the WHO trials search portal (both accessed 10 Feb 2014) using \'malaria\*\', \'falciparum\', and \'Primaquine\' as search terms.

#### Conference proceedings

We searched the following conference proceedings for relevant abstracts: the MIM Pan-African Malaria Conferences and the American Society of Tropical Medicine and Hygiene (ASTMH) to December 2009.

### Searching other resources

#### Researchers and organizations

We contacted researchers at the London School of Hygiene and Tropical Medicine who were authors of some of the included and in-progress trials, and other experts in the field of malaria chemotherapy, including those based at WHO.

#### Reference lists

We checked the reference lists of all studies identified by the above methods.

Data collection and analysis
----------------------------

### Selection of studies

Two authors (PMG and HG) independently screened all citations and abstracts identified by the search strategy, including ongoing studies, for potentially eligible studies. We independently assessed full reports of potentially eligible studies for inclusion in the review. Notably, we did not contact any trial authors for clarification regarding inclusion (although we later contacted several about trial details) because it was clear whether trials were or were not eligible for inclusion. We used translations of eight papers published in Chinese to assess eligibility. We resolved differences of opinion by discussion with PG. There was one instance of duplicate reports of the same trial in different languages.

### Data extraction and management

Two authors (PMG and HG) independently extracted the following information for each trial using a data extraction form.

#### Characteristics of trial

-   Design (RCT or quasi-RCT, type of randomization)

-   Dates and duration of trial

#### Characteristics of participants

-   Number of participants

-   Age and sex of participants

-   Proportion with G6PD deficiency

-   Proportion with gametocytes at onset of trial

-   Inclusion criteria

-   Exclusion criteria

#### Characteristics of interventions

-   Type of drug, dose, and schedule

#### Presented outcomes

-   Description of outcomes presented in the papers

#### Other

-   Location of trial, setting, and source of funding

-   Local endemicity of malaria

#### Outcomes data

For each trial, PMG and HG extracted data on the trial outcomes eligible for inclusion in this review for the PQ and non-PQ groups. We extracted the number of participants randomized and the numbers analysed in each treatment group for each outcome. For dichotomous data outcomes (proportion of participants with gametocytes or asexual stages, proportion of participants infectious to mosquitoes, and proportion of mosquitoes infected), we extracted the number of participants experiencing the event of interest and the total number of patients or mosquitoes in each treatment arm of each trial. For continuous outcomes (AUC for gametocyte numbers over time), we extracted arithmetic or geometric means and standard deviations for each treatment group by day of assessment, together with the number of patients in each group. We noted details on the method of determining parasite presence and density, for example light microscopy (if so, the method of staining and number of fields examined), PCR or other methods.

For G6PD deficiency, we noted the sex of the carrier (if stated) and the method used to determine G6PD deficiency, either phenotypically (by enzyme function) or PCR (by genotype). We adopted the definition of \'deficient\' used in the trials that assessed this outcome. We extracted adverse event data for each individual type of event wherever possible. Where adverse events were reported separately for more than one dose (for short-course regimens), we attempted to record the average number of people reporting each adverse event for each dose. If trials reported the occurrence of adverse events at more than one time point following a single dose, but did not record the total number of people reporting each event, we attempted to record the events occurring in the first time period.

In cases of disagreement, we double checked the data and we reached consensus through discussion between all three authors.

### Assessment of risk of bias in included studies

PMG and HG independently assessed the risk of bias of the included trials as recommended in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins [@b95]). For each included trial, we assigned a score of low, unclear or high risk of bias for the following components: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessors, incomplete outcome data, selective outcome reporting, and other biases.

For sequence generation and allocation concealment, we described the methods used, if given. For blinding, we described who was blinded and the blinding method. For incomplete outcome data, we reported the percentage and proportion of loss to follow-up (the number of patients for whom outcomes are not measured of the number randomized), if given. For selective outcome reporting, we stated any discrepancies between the methods and the results in terms of the outcomes measured and the outcomes reported; we also stated if we knew that an outcome was measured but was not reported in the publication. For other biases we described any other trial features that could have affected the trial\'s results (for example, whether a trial was stopped early or if no sample size calculation was included). We resolved any disagreements through discussion.

We reported the results of the risk of bias assessment in a \'Risk of bias\' table and displayed them in a \'Risk of bias\' summary and \'Risk of bias\' graph (Figure Figure [2](#fig02){ref-type="fig"}; Figure Figure [3](#fig03){ref-type="fig"}).

![Risk of bias summary: review authors\' judgements about each risk of bias item for each included trial](CD008152-0001-f2){#fig02}

![Risk of bias graph: review authors\' judgements about each risk of bias item presented as percentages across all included trials](CD008152-0001-f3){#fig03}

### Measures of treatment effect

We analysed the data using Review [@b108]. For dichotomous data, we estimated the Risk Ratio (RR) and used the Mantel-Haenszel method with fixed-effect, or with random-effects if there was heterogeneity. For continuous data, we estimated the mean difference (MD). All results are presented with 95% confidence intervals (CIs). We reported results only for days after the first day of PQ treatment, which, in some trials, was later than the beginning of primary treatment.

If trials reported gametocyte outcomes for days 1, 8, 15, 29, and 43, we estimated AUC using either the summary gametocyte measures reported by group in the paper, or by calculation from individual patient data supplied by the authors. Since few patients had gametocytes up to day 43, we also estimated AUC only up to day 15 and day 29 for the same trials. The AUC is a weighted sum of gametocyte densities, with weights proportional to the difference in time between adjacent sampling points as described by Dunyo [@b89] and Mendez [@b102] in trials assessing gametocytaemia after sulfadoxine-pyrimethamine (SP) treatment. However, Mendez [@b102] used follow-up days 4 to 22 (reported as days 3 to 21 in trial), which do not encompass the early days of highest gametocytaemia nor the participants who still had gametocytes after day 21.

We used the following formulas:

AUC (days 1 to 15) = ((8-1)\*(G1+G8)/2)+((15-8)\*(G15+G8)/2)/14 for days 1 through 15

AUC (days 1 to 29) = ((8-1)\*(G1+G8)/2)+((15-8)\*(G15+G8)/2)+((29-15)\*(G29+G15)/2)/28 for days 1 through 29

AUC (days 1 to 43) = ((8-1)\*(G1+G8)/2)+((15-8)\*(G15+G8)/2)+((29-15)\*(G29+G15)/2)+((43-29)\*(G43+G29)/2)/42 for days 1 through 43

where Gx = mean gametocyte density on day X (estimated using data from all participants still enrolled on day X). We estimated log(10)AUC values using geometric mean gametocyte density.

When one trial contained more than one comparison with the same placebo group and there was an analysis total or subtotal, we divided the placebo group participants between the comparisons to avoid underestimating the CI.

### Unit of analysis issues

All the included trials were individually randomized and analysed. No cluster-RCTs met the inclusion criteria for the review.

### Dealing with missing data

Where data were missing from the trials or details were unclear, we attempted to contact the authors. We used complete case analysis for trials with missing data.

### Assessment of heterogeneity

We assessed heterogeneity between the trials by examining the forest plots to check for overlapping CIs, using the Chi^2^ test for heterogeneity with a 10% level of significance, and the I^2^ statistic using a value of 50% to represent moderate levels of heterogeneity.

### Assessment of reporting biases

There were insufficient trials within each comparison to assess the likelihood of small trial effects, such as publication bias, by examining a funnel plot for asymmetry.

### Data synthesis

We stratified trials by non-artemisinin or artemisinin based malaria treatment regimens and described which antimalarial drug was used for each comparison in the footnote. Also we stratified by PQ dose category: low (\< 0.4 mg/kg) medium (≥ 0.4 to \< 0.6 mg/kg); and high (≥ 0.6 mg/kg dose); by schedule (single dose day 1 or 2, single dose day 3 or 4, and multiple dose days 1 to 7) and grouped the 8AQ drugs as PQ and other. Throughout this review, we designated the first day of treatment as day 1 rather than day 0 as reported in some trials.

Where not stated as mg/kg, we reported the PQ dose as the adult dose with the equivalent dose reported as mg/kg; most trials stated that the dose was adjusted for children and we made this assumption if not.

When there was no statistically significant heterogeneity between trials, we applied the fixed-effect meta-analysis model. When we observed statistically significant heterogeneity within groups that could not be explained by subgroup or sensitivity analyses, we used a random-effects meta-analysis model. When we determined substantial heterogeneity from the assessments of heterogeneity (such as high I^2^ value, low Chi^2^ statistic P value, or when a pooled meta-analysis result was considered meaningless because of clinical heterogeneity) we did not undertake meta-analysis but instead presented a forest plot with the pooled effect suppressed.

### Subgroup analysis and investigation of heterogeneity

In our protocol, we stated we would investigate heterogeneity in relation to drug resistance pattern, the parasite density before treatment and the local endemicity of malaria. However, we identified too few trials for this analysis. We stratified outcomes under comparisons 1 and 2 (non-artemisinin-based and artemisinin-based partner respectively) by time point after treatment, by dose and by schedule of PQ where possible.

We stratified Comparison 3 by artemisinin-based and non-artemisinin-based partners. In this case, we assessed the outcome of percentage of people with gametocytes on day 8 only and combined all trials in each subgroup that started PQ any time up to day 7.

When we did not detect statistically significant heterogeneity between trials, we applied the fixed-effect meta-analysis model. When there was statistically significant heterogeneity within groups that could not be explained by subgroup or sensitivity analyses, we used a random-effects meta-analysis model.

When substantial heterogeneity was determined from the assessments of heterogeneity (such as high I^2^ value, low Chi^2^ statistic P value, or when we considered a pooled meta-analysis result meaningless because of clinical heterogeneity), we did not perform meta-analysis but instead presented a forest plot with the pooled effect suppressed.

### Sensitivity analysis

There were insufficient trials to conduct a sensitivity analysis to investigate the robustness of the results to the quality (risk of bias) components.

Results
=======

Description of studies
----------------------

### Results of the search

In the first version of this review (Graves [@b119]), we identified 45 potentially relevant publications from literature searches. Two publications (in different languages) described the same trial (Chen [@b3]), leaving 44 distinct trials. We excluded 13 at abstract stage, excluded 20 after reading the full text article, and included 11 trials in the review.

For this update, we repeated the searches since we had expanded the scope of the review to include other 8AQ and comparisons of different doses of PQ and other 8AQ. We identified 65 more potential studies in addition to the 45 previously identified, which we rescreened due to revised inclusion criteria. We identified an additional 41 papers from reference lists, personal knowledge of new papers, or people consulted. Of the 151 abstracts we screened, we selected 73 for full text review. Five papers were duplicates, we could not locate three articles, and we included 18 trials (Figure [4](#fig04){ref-type="fig"}). These 18 trials included a total of 30 distinct comparisons of different malaria treatment drugs, doses or schedules.

![Study flow diagram](CD008152-0001-f4){#fig04}

### Included studies

All 18 included trials were RCTs or quasi-RCTs. Two trials compared PQ and bulaquine, while 16 trials compared PQ versus no PQ. One trial of PQ (Khoo [@b9]) did not distinguish between short or long course of PQ and therefore no outcomes are included in this review. One trial did not include any gametocyte outcomes (Wang [@b18]).

Sixteen trials examined the impact of PQ or 8AQ on various measures of potential infectiousness, such as gametocyte prevalence over time or density in participants after treatment, gametocyte clearance time or gametocyte circulation time. Most trials assessed gametocyte prevalence by microscopy but two trials reported both microscopy and PCR (Shekalaghe [@b13]; Eziefula [@b5]) and one reported only PCR detection ([@b4]).

Two trials (Shekalaghe [@b13]; Eziefula [@b5]) reported log(10)AUC as a summary combined measure of gametocyte prevalence and density over time, using PCR estimates of density. For gametocytes detected by microscopy, we calculated the outcomes of AUC and log(10)AUC for four additional studies that provided appropriate information, either in the publications or from the authors (Vasquez [@b17]; Smithuis [@b15]; Kolaczinski [@b10]; Sutanto [@b19]).

For direct measures of infectiousness, two small trials in China (Chen [@b2]; Chen [@b3]) evaluated the infectiousness to mosquitoes of people treated with mefloquine (MQ) compared to MQ+PQ.

Only five trials reported adverse effects quantitatively: three for anaemia outcomes ([@b4]; Shekalaghe [@b13]; Eziefula [@b5]) and two for other outcomes (Wang [@b18]; Sutanto [@b19]).

No community trials examining malaria transmission intensity (measuring incidence of malaria, prevalence or EIR) met the inclusion criteria.

#### Participants

Participants were people attending health clinics for treatment. Four trials did not state the participants\' ages (Chen [@b2]; Chen [@b3]; [@b4]; Khoo [@b9]), and three trials included children only: Singhasivanon [@b14] (5 to 12 years); Shekalaghe [@b13] (3 to 15 years); and Eziefula [@b5] (1 to 10 years). Six trials used a wide age range of children and adults: Wang [@b18] (6 to 60 years); Vasquez [@b17] (≥ 1 year); Smithuis [@b15] (= six months); Arango [@b1] (1 to 75 years); Kolaczinski [@b10] (3 to 70 years); and Sutanto [@b19] (≥ 5 years). The remaining five studies included teenagers and adults only: Gogtay [@b6] (= 18 years); Kamtekar [@b8] (= 16 years); Pukrittayakamee [@b12] (15 to 62 years); Gogtay [@b7] (= 16 years); and Ledermann [@b11] (≥ 15 years). See the Characteristics of included studies section.

For G6PD deficiency, two studies did not screen participants (Kamtekar [@b8]; Smithuis [@b15]), one trial screened and included all participants (Shekalaghe [@b13]), one trial included only G6PD-deficient participants (Khoo [@b9]), six studies included only non-deficient participants (Gogtay [@b6]; Pukrittayakamee [@b12]; Gogtay [@b7]; Ledermann [@b11]; Eziefula [@b5]; Sutanto [@b19]), and the remaining eight studies made no comment (Chen [@b2]; Chen [@b3]; Singhasivanon [@b14]; Wang [@b18]; [@b4]; Vasquez [@b17]; Arango [@b1]; Kolaczinski [@b10]); see [Table 1](#tbl1){ref-type="table"}. Table 1G6PD status, partner drugs, gametocyte status at onset, and PQ dose and treatment scheduleComparatorTrialComparisonPlaceG6PD statusParasite speciesPartner or alternative drugProportion with gametocytes at onset (by microscopy unless noted)PQ day(s)\*Target PQ dose per day**Non-artemisinin partner**CQ or (CQ+SP)Kamtekar [@b8]aIndia (Mumbai)Not screenedPf onlyCQ days 1 to 3 or CQ days 1 to 3 + SP day 1100% (within 3 days) (N = 46)day 445 mg (˜0.75 mg/kg)Khoo [@b9]Malaysia (Sabah)Only deficient (method: Brewer\'s methaemoglobin reduction test)Pf, Pv or mixedCQ days 1 to 3Not reporteddays 1 to 325 mg (˜0.42 mg/kg)Kolaczinski [@b10]aPakistan (3 Afghan refugee camps)Not reportedPf onlyCQ days 1 to 317.8% (N = 152)day 30.5 mg/kgLedermann [@b11]aIndonesia (Central Java)Only non-deficient (method: semiquantitative glucose-6-phosphate dehydrogenase (G6PD) assay)Pf onlyCQ days 1 to 3 + SP day 1Not reported (N = 60)day 145 mg (˜0.75 mg/kg)Ledermann [@b11]bIndonesia (Central Java)Only non-deficient (method: semiquantitative glucose-6-phosphate dehydrogenase (G6PD) assay)Pf onlyCQ days 1 to 3 + SP day 1Not reported (N = 60)day 345 mg (˜0.75 mg/kg)SPKolaczinski [@b10]bPakistan (2 Afghan refugee camps)Not reportedPf onlySP day 127.1% (N = 85)day 10.5 mg/kgAQ+SPArango [@b1]aColombiaNot reportedPf onlyAQ days 1 to 3 + SP day 122.5% (N = 40)day 20.75 mg/kgMQ or (MQ+SP)Chen [@b2]ChinaNot reportedPf onlyMQ day 1100% (N = 12)day 145 mg (˜0.75 mg/kg)Chen [@b3]China (Hainan province)Not reportedPf onlyMQ day 1100% (N = 18)day 145 mg (˜0.75 mg/kg)Singhasivanon [@b14]Thailand (Bangkok)Not reportedPf onlyMQ+SP fixed day 1Not reported (N = 18)day 10.75 mg/kgQNKamtekar [@b8]bIndia (Mumbai)Not screenedPf onlyQN i.v. days 1 to 2 and orally days 1 to 7100% (within 3 days) (N = 43)day 845 mg (˜0.75 mg/kg)Pukrittayakamee [@b12]aThailandPatients with G6PD deficiency were excluded from getting PQ (method not reported)Pf onlyQN days 1 to 718.6% (N = 59)days 1 to 70.25 mg base/kgPukrittayakamee [@b12]bThailandPatients with G6PD deficiency were excluded from getting PQ (method not reported)Pf onlyQN days 1 to 722.4% (N = 67)days 1 to 70.5 mg base/kg**Artemisinin-based partner**AS or ACTArango [@b1]bColombiaNot reportedPf onlyAS+MQ days 1 to 317.1% (N = 42)day 20.75 mg/kg[@b4]Sudan (east)Not reportedPf onlyAS+SP days 1 to 33.8% (N = 104) 11.6% PCR (N = 95)day 40.75 mg/kgEziefula [@b5]aUgandaPatients without normal G6PD were excluded (method fluoresence spot test)Pf onlyAL days 1 to 324.3% (N = 115) 86.7% PCR (N = 113)day 30.1 mg/kgEziefula [@b5]bUgandaPatients without normal G6PD were excluded (method fluoresence spot test)Pf onlyAL days 1 to 320.4% (N = 113) 78.7% PCR (N = 108)day 30.4 mg/kgEziefula [@b5]cUgandaPatients without normal G6PD were excluded (method fluoresence spot test)Pf onlyAL days 1 to 322.4% (N = 116) 82.0% PCR (N = 111)day 30.75 mg/kgPukrittayakamee [@b12]cThailandPatients with G6PD deficiency were excluded from getting PQ (method not reported)Pf onlyAS days 1 to 726.0% (N = 50)days 1 to 70.5 mg base/kgShekalaghe [@b13]Tanzania (North east)Screened and all included (method: detection of single nucleotide polymorphisms in the human G6PD gene (G202A,A376G) by a simple high throughput PCR using sequence specific oligo-nucleotide probes (SSOPs) and ELISA testing)Pf onlyAS+SP days 1 to 322.6% (N = 106) 87.7% PCR (N = 106)day 40.75 mg/kgSmithuis [@b15]aMyanmar (3 states)Not screenedPf or mixedAS+AQ days 1 to 334% (N = 155)day 10.75 mg/kgSmithuis [@b15]bMyanmar (3 states)Not screenedPf or mixedAL days 1 to 333% (N = 152)day 10.75 mg/kgSmithuis [@b15]cMyanmar (3 states)Not screenedPf or mixedAS+MQ fixed dose days 1 to 330% (N = 169)day 10.75 mg/kgSmithuis [@b15]dMyanmar (3 states)Not screenedPf or mixedAS days 1 to 3 + MQ day 1 loose29% (N = 161)day 10.75 mg/kgSmithuis [@b15]eMyanmar (3 states)Not screenedPf or mixedDHAP days 1 to 338% (N = 161)day 10.75 mg/kgSutanto [@b19]Indonesia (south Sumatra)Screened and only normals included (method: qualitative test)Pf onlyDHAP days 1 to 320.6% (on day 3) (N = 349)day 30.75 mg/kgVasquez [@b17]Colombia (Antioquia)Not reportedPf onlyAS+MQ days 1 to 3 (MQ only on day 2 for children \< 6)20.0% (N = 50)day 345 mg (˜0.75 mg/kg)Wang [@b18]GabonNot reportedPfAS i.m. days 1 to 5Not reported (N = 204)days 1 to 522.5 mg (˜0.38 mg/kg)**Comparison of different 8AQ**PQ versus BulaquineGogtay [@b6]India (Mumbai)Only non-deficient (method: not stated)PfQN + doxycycline days 1 to 7 + BQ day 4100% (N = 22)day 445 mg (˜0.75 mg/kg)Gogtay [@b7]IndiaOnly non-deficient (method: not stated)PfQN + doxycycline days 1 to 7 + BQ day 4100% (N = 93)day 445 mg (˜0.75 mg/kg)[^14]

#### Interventions

##### Non-artemisinin-based regimens

Twelve studies (15 treatment arms) evaluated PQ given alongside non-artemisinin-based treatments: chloroquine alone (CQ) (two trials), CQ+sulfadoxine-pyrimethamine (SP) (one trial), CQ alone or CQ+SP (one trial), SP (one trial), mefloquine (MQ) (two trials), MQ+SP (two trials), quinine (QN) (two trials), and QN plus doxycycline (two trials).

##### Artemisinin-based regimens

Eight studies (15 treatment arms) evaluated PQ given alongside artemisinin-based treatments: artesunate (AS) (two trials), AS+SP (two trials), AS+MQ (four trials), AS+amodiaquine (AQ) (one trial), artemether-lumefantrine (AL) (four trials) and dihydroxyartemisinin-piperaquine (DHAP) (two trials).

##### Dose

Most trials used a target dose equivalent to 0.75 mg/kg PQ per day (adult dose 45 mg/day), see [Table 1](#tbl1){ref-type="table"}. The exceptions were:

-   Khoo [@b9]: adult dose of 25 mg or approximately 0.42 mg/kg/day;

-   Kolaczinski [@b10]: (two comparisons) 0.5 mg/kg or adult dose 30 mg/day;

-   Pukrittayakamee [@b12]: the trial with QN had two arms, one with 0.25 mg/kg and the other 0.5 mg/kg per day (adult dose 15 mg or 30 mg per day respectively); the comparison with AS used 0.5 mg/kg per day (adult dose 30 mg per day).

-   Wang [@b18]: adult dose of 22.5 mg or approximately 0.38 mg/kg per day.

-   Eziefula [@b5]: evaluated 0.1, 0.4 and 0.75 mg/kg and placebo.

##### Schedule

Most trials used a single dose of PQ given on the following days, and we regarded the first day of any treatment as day 1:

-   Day 1: Chen [@b2]; Chen [@b3]; Singhasivanon [@b14]; Ledermann [@b11] (one of two comparisons); Smithuis [@b15] (five comparisons); and Kolaczinski [@b10] (one of two comparisons);

-   Day 2: Arango [@b1] (two comparisons);

-   Day 3: Ledermann [@b11] (one of two comparisons); Vasquez [@b17]; Kolaczinski [@b10] (one of two comparisons); Eziefula [@b5]; and Sutanto [@b19];

-   Day 4: Gogtay [@b6]; Kamtekar [@b8] (one of two comparisons); Gogtay [@b7]; [@b4]; and Shekalaghe [@b13];

-   Day 8: Kamtekar [@b8] (one of two comparisons).

Three trials used a longer course of PQ:

-   3 days: Khoo [@b9];

-   5 days: Wang [@b18];

-   7 days: Pukrittayakamee [@b12] (three comparisons).

##### Prevalence of gametocytes at start of trial

Five trials only included people with gametocytes at onset (as detected by microscopy) (Chen [@b2]; Chen [@b3]; Gogtay [@b6]; Kamtekar [@b8] (both comparisons); Gogtay [@b7]). However Kamtekar [@b8] reported this variable as \"within 3 days\" rather than on day 1. Four trials did not report this statistic (Khoo [@b9]; Singhasivanon [@b14]; Ledermann [@b11] (both comparisons); Wang [@b18]).

In the remaining trials, one had low gametocyte prevalence at onset ([@b4], prevalence by microscopy 3.8%, by PCR 11.8%). Trials with initial prevalence between 17.1% and 27.1% were: Pukrittayakamee [@b12] (all three comparisons); Vasquez [@b17]; Arango [@b1]; Kolaczinski [@b10] (both comparisons); Eziefula [@b5]; and Sutanto [@b19]. Shekalaghe [@b13] reported gametocyte prevalence by microscopy of 22.6% but by PCR of 87.7%. Eziefula [@b5] observed a similar ratio between microscopy and PCR prevalence, with microscopy prevalence by arm of 20.4% to 24.3% and PCR prevalence of 78.4% to 86.7%. Excluding trials that included only gametocyte carriers, the five arms of the Smithuis [@b15] trial showed the highest prevalences, with gametocyte prevalence (microscopy) between 29% and 38%.

The details of the trial locations, malaria treatments, gametocyte prevalence, PQ doses and schedules are in [Table 1](#tbl1){ref-type="table"}.

### Excluded studies

We have listed the reasons for exclusion of 47 trials in the Characteristics of excluded studies section. Some additional details are given here.

Six community-based trials did not meet criteria for inclusion. Both Hii [@b39] (MDA with SP+PQ (30 mg adult dose, 0.5 mg/kg) + insecticide treated net (ITN) versus ITN only in Sabah, Malaysia) and Shekalaghe [@b59] (MDA with SP+AS+PQ (0.75 mg/kg) versus placebo) did not have appropriate comparison groups. Doi [@b35] was a community-based observational trial of mass test and treat with SP+PQ (0.7 to 1 mg/kg) in one intervention village, two schools in two other intervention villages, and one control village (SP only) on the coast of north Sumatra, Indonesia. There was no \'before\' data from these villages, and in the control site it appears that some children received treatment with PQ. Kaneko [@b46], also in north Sumatra, Indonesia, tested mass fever test and treat and/or mass test and treat in school children. The drugs used were SP+PQ in one intervention village and SP in one control village. Apart from there being only one cluster (village) per arm and non-randomized, the main reason for exclusion was the intensity of effort on case detection appeared much greater in the intervention village, resulting in 75% of people in the intervention village being treated over a 29-day period versus 18% in the control village over a 14-day period. The Barber [@b21] trial in Liberia was a trial of MDA that administered the 8AQ plasmoquine approximately twice weekly to ˜133 people for periods ranging from nine to 28 days with follow up for several weeks. Plasmoquine had a large (although short-lived) impact on transmission in this trial. However the main reasons for its exclusion were the lack of malaria treatment given together with plasmoquine, non-comparable control site and lack of parasite outcomes in the control group. In the MDA trial of Clyde [@b30] in Tanzania, AQ+PQ was given every 1, 2 or 4 weeks to over 93% of the populations residing in three sites near Morogoro, Tanzania for periods ranging by site between 26 and 39 weeks. The dose of PQ was 30 mg (˜0.5 mg/kg for an adult) given to everyone over six years of age, with half dose given to those aged between 0 and five years. Transmission was greatly reduced, especially in the sites receiving MDA every one or two weeks (although transmission was not interrupted). We excluded this trial because everyone received malaria treatment as well as PQ, so the additional impact of PQ cannot be assessed.

Several controlled or uncontrolled before-and-after studies, and non-randomized comparative case series or trials, were excluded. They were generally studies of small numbers of individuals on whom mosquitoes were fed before and after they ingested PQ, with or without other malaria treatment. These studies, which include Barber [@b20], Barber [@b21], Jerace [@b45], Mackerras [@b53], Jeffery [@b43], Young [@b65], Gunders [@b38], Jeffery [@b44], Rieckmann [@b54], Rieckmann [@b55], Clyde [@b31], and Clyde [@b32], have been reviewed by White [@b114] and White [@b115] but did not meet our inclusion criteria. Abay [@b76] also reviewed two of these before-and-after studies which had four patients in total (Rieckmann [@b54]; Clyde [@b32]). Two studies used varying doses of PQ (Jeffery [@b43], Rieckmann [@b55]), as did Burgess [@b24] and Bunnag [@b26]. However, Burgess [@b24] gave doses according to participants\' age rather than testing different doses in comparable patients, and there was no other malaria treatment drug given. In Bunnag [@b26] all received malaria treatment (SP) in addition to PQ.

We sought publications for Chinese trials cited in White [@b114], White [@b115] and by personal communication from Professor Li Guo Qiao. We were unable to locate two (Chen [@b66]; Li [@b68]); the others were translated where required. We excluded the following studies on the basis of no appropriate comparison (either all groups got PQ or there was no comparator group with same dose of malaria treatment drug but no PQ) (Yang [@b63]; Che [@b28]; Che [@b27]; Huang [@b41]; Lin [@b52]; and Sun [@b60]) or lack of randomization (Cai [@b29] and Huang [@b40]). Three other trials of artemether with and without PQ in Africa (Huang [@b42], Li [@b50], and Li [@b51]) were stated to be randomized, but were excluded due to the late administration of PQ (after five to seven days of artemether) and lack of gametocyte outcomes.

Risk of bias in included studies
--------------------------------

Of the 18 included studies, the risk of bias assessment for concealment of allocation was adequate in 4 studies; methods of random allocation were adequate in 10; and blinding of outcome assessment adequate in 7; see Figure [2](#fig02){ref-type="fig"} and Figure [3](#fig03){ref-type="fig"}.

Pukrittayakamee [@b12] excluded G6PD-deficient people from the PQ group post-randomization. We had no reason to suppose it biased the primary outcomes but it could have affected assessment of adverse effects.

Effects of interventions
------------------------

See: **Summary of findings for the main comparison** Summary of findings table 1; **Summary of findings 2** Summary of findings table 2

For malaria transmission intensity (prevalence, incidence or EIR) we found no community cluster-RCTs measuring these outcomes. Regarding infectiousness, two trials (Chen [@b2]; Chen [@b3]) measured this in 12 and 18 patients respectively for non-artemisinin drugs, (in both cases MQ) with and without PQ.

All other trials reported potential infectiousness: the effects of PQ on gametocyte prevalence, density or clearance time, or all three outcomes. Only Shekalaghe [@b13] and Eziefula [@b5] reported a summary measure of potential infectiousness using AUC of gametocyte density over time; we calculated this for four other trials with available data. We estimated the AUC for microscopy-determined densities for trials of both non-artemisinin and artemisinin based malaria treatments. In the former category we had only Kolaczinski [@b10] (two comparisons). There were four trials with this information for artemisinin-based partners: Shekalaghe [@b13], Smithuis [@b15] (five comparisons), Sutanto [@b19], and Vasquez [@b17]. The estimate used the mean (or geometric mean) gametocyte density by group at a sequence of reported days of measurement. Since trials were not consistent in the days on which they estimated gametocyte density, we used the days on which measurements were available for all trials (days 1, 8, 15, 29 and 43; see Methods section). We estimated AUC up to day 15 ([Table 2](#tbl2){ref-type="table"}), day 29 ([Table 3](#tbl3){ref-type="table"}) and day 43 ([Table 4](#tbl4){ref-type="table"}). Results are presented separately by non-artemisinin-based and artemisinin-based malaria treatments below and given for log(10)AUC in the summary of findings tables for days 1 to 43.

###### 

AUC of gametocyte density over time, days 1 to 15 after treatment

  **Other malaria treatment type**   **Trial**            **Malaria treatment**   **Dose PQ mg/kg**   **AUC with PQ days 1 to 15**   **AUC without PQ days 1 to 15**   **% reduction AUC days 1 to 15**   **log(10)AUC with PQ days 1 to 15**   **log(10)AUC without PQ days1 to 15**   **% reduction log(10)AUC days 1 to 15**
  ---------------------------------- -------------------- ----------------------- ------------------- ------------------------------ --------------------------------- ---------------------------------- ------------------------------------- --------------------------------------- -----------------------------------------
  Non-artemisinin- based             Kolaczinski [@b10]   a: CQ                   0.5                 485.26                         4266.61                           88.6                               2.69                                  3.63                                    26.0
                                                                                                                                                                                                                                                                                        
                                     Kolaczinski [@b10]   b: SP                   0.5                 924.87                         5964.77                           84.5                               2.97                                  3.78                                    21.4
                                                                                                                                                                                                                                                                                        
  Artemisinin- based                 Shekalaghe [@b13]    AS+SP                   0.75                40.15                          65.06                             38.3                               1.60                                  1.81                                    11.6
                                                                                                                                                                                                                                                                                        
                                     Smithuis [@b15]      a: AS+AQ                0.75                140.35                         428.51                            67.3                               2.15                                  2.63                                    18.4
                                                                                                                                                                                                                                                                                        
                                     Smithuis [@b15]      b: AL                   0.75                196.24                         242.86                            19.2                               2.29                                  2.39                                    3.9
                                                                                                                                                                                                                                                                                        
                                     Smithuis [@b15]      c: AS+MQ fixed          0.75                237.78                         510.03                            53.4                               2.38                                  2.71                                    12.2
                                                                                                                                                                                                                                                                                        
                                     Smithuis [@b15]      d: AS+MQ loose          0.75                183.51                         293.28                            37.4                               2.26                                  2.47                                    8.3
                                                                                                                                                                                                                                                                                        
                                     Smithuis [@b15]      e: DHAP                 0.75                295.24                         709.60                            58.4                               2.47                                  2.85                                    13.4
                                                                                                                                                                                                                                                                                        
                                     Sutanto [@b19]       DHAP                    0.75                1252.48                        2355.84                           46.8                               3.10                                  3.37                                    8.1
                                                                                                                                                                                                                                                                                        
                                     Vasquez [@b17]       AS+MQ                   0.75                500.40                         305.67                            -63.7                              2.70                                  2.49                                    -8.6

###### 

AUC of gametocyte density over time, days 1 to 29 after treatment

  **Other malaria treatment type**   **Trial**            **Malaria treatment**   **Dose PQ mg/kg**   **AUC with PQ days 1 to 29**   **AUC without PQ days 1 to 29**   **% reduction AUC days 1 to 29**   **log(10)AUC with PQ days 1 to 29**   **log(10)AUC without PQ days 1 to 29**   **% reduction log(10)AUC days 1 to 29**
  ---------------------------------- -------------------- ----------------------- ------------------- ------------------------------ --------------------------------- ---------------------------------- ------------------------------------- ---------------------------------------- -----------------------------------------
  Non-artemisinin- based             Kolaczinski [@b10]   a: CQ                   0.5                 732.98                         8777.24                           91.7                               2.87                                  3.94                                     27.3
                                                                                                                                                                                                                                                                                         
                                     Kolaczinski [@b10]   b: SP                   0.5                 2111.55                        12847.37                          83.6                               3.32                                  4.11                                     19.1
                                                                                                                                                                                                                                                                                         
  Artemisinin- based                 Shekalaghe [@b13]    AS+SP                   0.75                40.30                          87.69                             54.0                               1.61                                  1.94                                     17.4
                                                                                                                                                                                                                                                                                         
                                     Smithuis [@b15]      a: AS+AQ                0.75                141.08                         649.46                            78.3                               2.15                                  2.81                                     23.6
                                                                                                                                                                                                                                                                                         
                                     Smithuis [@b15]      b: AL                   0.75                197.57                         318.23                            37.9                               2.3                                   2.5                                      8.3
                                                                                                                                                                                                                                                                                         
                                     Smithuis [@b15]      c: AS+MQ fixed          0.75                240.79                         535.40                            55.0                               2.38                                  2.73                                     12.7
                                                                                                                                                                                                                                                                                         
                                     Smithuis [@b15]      d: AS+MQ loose          0.75                183.51                         321.96                            43.0                               2.26                                  2.51                                     9.7
                                                                                                                                                                                                                                                                                         
                                     Smithuis [@b15]      e: DHAP                 0.75                307.14                         952.93                            67.8                               2.49                                  2.98                                     16.5
                                                                                                                                                                                                                                                                                         
                                     Sutanto [@b19]       DHAP                    0.75                1363.10                        3108.05                           56.1                               3.13                                  3.49                                     10.3
                                                                                                                                                                                                                                                                                         
                                     Vasquez [@b17]       AS+MQ                   0.75                526.40                         349.04                            -50.8                              2.72                                  2.54                                     -7.0

###### 

AUC of gametocyte density over time, days 1 to 43 after treatment

  Other malaria treatment type   Trial                Malaria treatment   Dose PQ   AUC with PQ days 1 to 43   AUC without PQ days 1 to 43   \% reduction AUC days 1 to 43   log(10)AUC with PQ days 1 to 43   log(10)AUC without PQ days 1 to 43   \% reduction log(10)AUC days 1 to 43
  ------------------------------ -------------------- ------------------- --------- -------------------------- ----------------------------- ------------------------------- --------------------------------- ------------------------------------ --------------------------------------
  Non-artemisinin- based         Kolaczinski [@b10]   CQ                  0.5       71.02                      279.13                        74.6                            1.85                              2.45                                 24.3
                                                                                                                                                                                                                                                    
                                                      SP                  0.5       85.47                      445.65                        80.8                            1.93                              2.65                                 27.1
                                                                                                                                                                                                                                                    
  Artemisinin- based             Shekalaghe [@b13]    AS+SP               0.75      1.16                       3.22                          64.1                            0.06                              0.51                                 87.5
                                                                                                                                                                                                                                                    
                                 Smithuis [@b15]      AS+AQ               0.75      3.36                       19.29                         82.6                            0.53                              1.29                                 59.1
                                                                                                                                                                                                                                                    
                                                      AL                  0.75      4.70                       8.12                          42.1                            0.67                              0.91                                 26.1
                                                                                                                                                                                                                                                    
                                                      AS+MQ fixed         0.75      5.73                       12.75                         55.0                            0.76                              1.11                                 31.4
                                                                                                                                                                                                                                                    
                                                      AS+MQ loose         0.75      4.37                       7.74                          43.5                            0.64                              0.89                                 27.9
                                                                                                                                                                                                                                                    
                                                      DHAP                0.75      7.38                       25.49                         71.1                            0.87                              1.41                                 38.3
                                                                                                                                                                                                                                                    
                                 Sutanto [@b19]       DHAP                0.75      32.73                      83.15                         60.6                            1.51                              1.92                                 21.1
                                                                                                                                                                                                                                                    
                                 Vasquez [@b17]       AS+MQ               0.75      12.53                      8.87                          -41.3                           1.10                              0.95                                 -15.8

### Primaquine plus non-artemisinin-based treatment regimens (Comparison 1)

Eleven trials contributed comparisons to this analysis, of which one trial tested a low dose PQ regimen (Pukrittayakamee [@b12]). One trial (Khoo [@b9]) did not report results in a usable manner.

#### Gametocyte prevalence

There were fewer people with gametocytes (detected by microscopy) in the PQ group at days 8, 15, 22, 29 and 36 (Analysis 1.1). The largest number of trials and comparisons was included at day 8 (RR 0.60, 95% CI 0.50 to 0.73, six trials, 498 participants, nine comparisons) and the effect appeared larger at day 15 (RR 0.31, 95% CI 0.22 to 0.43, four trials, 366 participants, seven comparisons).

The trials included three with CQ or CQ combination partner treatment (Kamtekar [@b8]; Ledermann [@b11] (two comparisons); Kolaczinski [@b10]); one with SP (Kolaczinski [@b10]); one with AQ+SP (Arango [@b1] (one comparison)); one with MQ (Chen [@b2]) and two with quinine (Kamtekar [@b8] (one comparison); Pukrittayakamee [@b12] (two comparisons)).

#### Gametocyte clearance time or duration of gametocyte carriage (the average number of days each person has gametocytes)

Gametocyte clearance time (in days) was significantly reduced in the PQ group in Singhasivanon [@b14] (which had MQ+SP partner) with a mean difference of -14.90 days (95% CI -18.18 to -11.62). (Analysis 1.2). The median gametocyte clearance time was also reduced in Pukrittayakamee [@b12] (two comparisons; partner QN) from 216 hours to 48 hours with 0.5 mg/kg PQ, or 87 hours with 0.25 mg/kg PQ, although results were not presented in a form that could be shown graphically.

#### AUC of gametocyte density over time

Gametocyte density over time up to day 43 was assessed by microscopy in the trial of Kolaczinski [@b10] (two comparisons). We analysed the data further using the AUC and log(10)AUC measures for days 1 to 15, 1 to 29 and 1 to 43, estimated from data provided by the authors ([Table 2](#tbl2){ref-type="table"}; [Table 3](#tbl3){ref-type="table"}; [Table 4](#tbl4){ref-type="table"})

Reductions in AUC for non-artemisinin malaria treatment regimens were 84.5% and 88.6% up to day 15, 83.6% and 91.7% up to day 29, and 74.6% and 80.8% up to day 43 (one trial, two comparisons). Using the log(10)AUC, for non-artemisinin malaria treatment regimens the estimates were 21.4% and 26.0% to day 15, 19.1% and 27.3% to day 29, and 24.3% and 27.1% to day 43 (one trial, two comparisons).

#### Infectiousness to mosquitoes

Two small trials in China (Chen [@b2]; Chen [@b3]), with only six and nine participants per group respectively, directly tested the impact of PQ added to MQ on infectiousness to mosquitoes. On day 1 all patients in the trial were infectious to *Anopheles dirus* mosquitoes, but after a dose of PQ on day 1 the proportion of people infectious was reduced to 0 when measured on days 2, 5 and 8 (Analysis 1.3). By day 15 and day 22 the difference was attenuated as infectiousness in the control group declined.

Chen [@b3] also reported the number of mosquitoes infected after feeding on trial participants (Analysis 1.4; note the CIs are not corrected for repeated observations in the same patients). None of the mosquitoes feeding on people receiving PQ were infected, with over 64% infected at day 5 after feeding on the group not receiving PQ, with the effect still evident up to day 22, although the proportion infected in the control group declined over time.

#### Asexual parasites at day 29 (recrudescence or reinfection)

In Kolaczinski [@b10] there was no effect of PQ (added to either CQ or SP) on prevalence of asexual parasites at day 29 (parasitological treatment failure), whether or not the results were adjusted for new infections detected by PCR (Analysis 1.5).

#### Asexual parasite clearance

There was no effect of PQ on asexual clearance time in Singhasivanon [@b14] (added to MQ+SP) or Pukrittayakamee [@b12] (two comparisons, added to QN) (Analysis 1.6).

#### Adverse effects

Patients with G6PD deficiency were excluded (two trials), the only patients included (one trial), not screened for (two trials), or not reported or commented on (six trials).

The trials with non-artemisinin regimens did not report adverse effects well or consistently. None of these trials reported on haemolysis, other haematological measures or severe adverse events.

Singhasivanon [@b14] found no difference in frequency of reported adverse effects (nausea, vomiting or dizziness) over 28 days follow-up (Analysis 1.7).

We could not use data from one trial with non-artemisinin partner, CQ, because it did not distinguish between patients with *P. falciparum* and *P. vivax* and their respective treatments (Khoo [@b9]). There was a much higher risk of adverse haemolytic events in those who received PQ in the Khoo [@b9] trial (OR of 22.27 for both haemolysis and need for blood transfusion), but we could not include the results because the groups combined participants receiving a short course (three days) of PQ with those receiving a 14-day regimen. The most unusual aspect of the trial, however, is that it only included individuals with G6PD deficiency.

#### Dose and schedule

***Dose of PQ:*** We stratified trials into low, medium and high dose category PQ. Only Pukrittayakamee [@b12] used the low dose category (0.25 mg/kg per day, given for seven days in conjunction with QN). It used medium dose category (0.5 mg/kg) at the same schedule also with QN, while Kolaczinski [@b10] used the 0.5 mg/kg medium dose in two comparisons (with CQ and SP). Three trials used the high dose category 0.75 mg/kg of PQ: Arango [@b1] in one comparison with AQ + SP); Ledermann [@b11] in two comparisons, both with CQ+SP, and Kamtekar [@b8] in one comparison with CQ or (CQ+SP).

With the low dose, there was no difference detected between the groups with and without PQ (Analysis 1.8, one trial), even though this dose of PQ was given for seven days (RR 1.76, 95% CI 0.97 to 3.18, 59 participants, one trial).

Both the medium and high dose reduced the prevalence of gametocytes at day 8: RR = 0.62 (95% CI 0.50 to 0.76) for medium dose, three comparisons; and RR 0.39 (95% CI 0.25 to 0.62 for high dose, five comparisons) (Analysis 1.8).

***Schedule of PQ:*** We stratified this comparison into three groups: single dose on day 1 or 2, single dose day 3 or 4, and multiple doses day 1 to 7. The comparison is indirect, although the schedule on day 3 or 4 seemed to have a greater effect. One arm of Ledermann [@b11] received PQ on day 1 and the other on day 3. There was no apparent difference in the outcome between these two arms (Analysis 1.9).

### Primaquine plus artemisinin-based treatment regimens (Comparison 2)

Nine trials contributed comparisons to this analysis, including ACTs (seven trials) and artemisinin monotherapy (two trials) for malaria treatment. Only one trial tested a low dose PQ regimen, 0.1 mg/kg total dose.

#### Gametocyte prevalence

Microscopy analysis revealed that PQ clearly reduced the number of people with gametocytes on day 8 (RR 0.24, 95% CI 0.10 to 0.55, six trials, 1121 participants, 10 comparisons), day 15 (RR 0.09, 95% CI 0.04 to 0.19, four trials, 995 participants, eight comparisons), day 22 (RR 0.10, 95% CI 0.03 to 0.32, three trials, 858 participants, seven comparisons, four with estimable results, 507 participants) and day 29 (RR 0.17, 95% CI 0.04 to 0.72, four trials, eight comparisons, four with estimable results) (Analysis 2.1). We used the random-effects model due to heterogeneity.

In Smithuis [@b15], new gametocytaemia (by microscopy) on day 8 was also reduced by PQ (one of 272 versus 10 of 268; RR 0.1, 95% CI 0.01 to 0.76, P = 0.006).

Three trials examined gametocytes by PCR rather than (or in addition to) microscopy. In Shekalaghe [@b13] and Eziefula [@b5], a reduction in gametocyte prevalence was observed on day 8 and day 15 (Analysis 2.2). However, in [@b4], giving PQ did not lead to a detectable difference between the two groups on these two follow-up days, although there were very few participants with gametocytes in the control group. Given the clear statistical and clinical heterogeneity between the two estimates (related to different numbers of participants with gametocytes in the comparator arm in these two studies) we used the random-effects model to combine the trials in meta-analysis (Analysis 2.2). In Shekalaghe [@b13] which had additional follow-up on day 29, reduction in gametocyte prevalence was significant (RR 0.23, 95% CI 0.08 to 0.62, one trial, 90 participants), and on day 43, it was not (one trial, 79 participants, Analysis 2.2).

Note that the trial of Eziefula [@b5] was reported as a non-inferiority analysis comparing lower dose groups with the previously recommended 0.75 mg/kg. In this review, in order to combine trials for analysis, results in each arm have been compared with the single placebo group, and where meta-analysis is done, numbers in the placebo group have been divided into three to avoid biasing the CIs.

#### Gametocyte clearance time or duration of gametocyte carriage (the length of time each person has gametocytes)

Several authors presented gametocyte clearance time, sometimes described as \"duration of gametocyte carriage\". This was presented in Shekalaghe [@b13] and was significantly lower (by PCR) in the PQ group (6.3 days, 95% CI 4.7 to 8.5) than in the non-PQ group (28.6 days, 95% CI 17.0 to 48.0, P \< 0.001). In Eziefula [@b5], also by PCR, the gametocyte clearance time was not significantly longer in the 0.1 mg/kg group (8.0 days, 95% CI 6.6 to 9.4) or the 0.4 mg/kg group (6.3 days, 95% CI 5.1 to 7.5) than the 0.75 mg/kg group (6.6 days, 95% CI 5.3 to 7.8); however this group had significantly shorter gametocyte clearance time than the placebo group (12.4 days, 95% CI 9.9 to 15.0). Smithuis [@b15], using microscopy, also reported significantly lower gametocyte clearance time in the PQ groups, reported as person-gametocytaemia-weeks standardized per 1000 person-weeks of follow-up. This was 5.5 weeks in the ACT+PQ groups versus 65.5 weeks in the non-PQ groups (RR 11.9, 95% CI 7.4 to 20.5, P \< 0.001) and the difference was very large for each individual malaria treatment regimen. Although the duration of gametocyte carriage (without PQ) was significantly longer for AS+AQ, AL and DHAP than for AS+MQ, there was no significant difference in length of gametocyte carriage between the ACT groups when PQ was added (Smithuis [@b15]).

#### Gametocyte circulation time

Another outcome related to gametocytes estimated by PCR in Eziefula [@b5] and Shekalaghe [@b13] was the mean life (circulation time) of gametocytes. In Eziefula [@b5] the circulation time per gametocyte was significantly longer in the 0.1 mg/kg group (1.47 days, 95% CI 1.22 to 1.73) than in the other two groups (0.95 and 0.98 days in the 0.4 and 0.75 mg/kg groups respectively), and was similar to the placebo group (1.97 days, 95% CI 1.64 to 2.31). In Shekalaghe [@b13], the mean gametocyte circulation time was reduced from 4.6 days (95% CI 2.9 to 7.3) after AS+SP alone to 0.5 days (95% CI 0.2 to 1.2) after AS+SP plus PQ (P \< 0.001).

#### AUC of gametocyte density over time

Gametocyte density over time was assessed by microscopy in the artemisinin-based regimen trials of Shekalaghe [@b13], Smithuis [@b15] (five comparisons), Sutanto [@b19] and Vasquez [@b17], and we analysed this further using data provided by the authors ([Table 2](#tbl2){ref-type="table"}; [Table 3](#tbl3){ref-type="table"}; [Table 4](#tbl4){ref-type="table"}). All trials except Vasquez [@b17] demonstrated reduction in the AUC after PQ. The reduction ranged from -63.7% to 67.3% up to day 15, -50.8% to 91.7% up to day 29, and from -41.3% to 82.6% up to day 43. Using the log(10)AUC, the reduction ranged from -8.6% to 18.4% up to day 15, from -7.0% to 27.3% up to day 29 and -15.8% to 87.5% up to day 43.

Vasquez [@b17] was an exception suggesting an increase in AUC after PQ, possibly due to the small sample size and differing mean gametocyte counts by group at baseline in this trial. Excluding Vasquez [@b17], reductions in AUC varied from 19.2% to 67.3% for days 1 to 15, from 37.9% to 91.7% for days 1 to 29, and 42.1% to 82.6% for days 1 to 43, using the mean gametocyte density. Using the log(10)AUC, the reduction ranged from 3.9% to 18.4% for days 1 to 15, 8.3% to 27.3% for days 1 to 29 and 24.3% to 87.5% for days 1 to 43.

Eziefula [@b5] used a duration of 14 days to estimate AUC using PCR, but the results were not reported separately by group and day so cannot be shown in [Table 2](#tbl2){ref-type="table"}. However the log(10)AUC in the intervention groups were not significantly different from placebo. It was 3.8 (95% CI 1.7 to 8.2) gametocytes per μL per day in the placebo group, 3.8 (1.8 to 7.8) in the 0.1 mg/kg group, 2.1 (1.0 to 4.5) in the 0.4 mg/kg group, and 2.0 (0.9 to 4.3) in the 0.75 mg/kg group.

Using PCR-detected gametocyte density estimates, Shekalaghe [@b13] provided geometric mean and interquartile range (IQR) values on days 1, 4, 8, 15, 29 and 43. Mean density was consistently lower in the PQ than the non-PQ group, for days when gametocytes were detected (with PQ: 5.8, IQR 0.8 to 55.1; without PQ: 15.8, IQR 4.1 to 85.8).

Shekalaghe [@b13] also presented a statistical comparison of AUC of gametocyte density (by PCR) over a 43-day period, with a 95% CI derived from generalized estimation equations. There was a significant reduction in AUC in the PQ groups over 43 days after treatment, reported as mean of 1.5 (IQR 0.3 to 8.8) in the PQ group versus 11.1 (IQR 2.2 to 53.8) in the non-PQ group (P \< 0.001).

#### Asexual parasite prevalence

Analysis 2.3 shows the participants who had asexual parasites at several time points after treatment. This analysis suggests a lower proportion of asexual parasites at day 29 in the PQ group reflecting possible recrudescence, late treatment failure or reinfection. However, Wang [@b18] did not adjust for reinfections by PCR. In the other trials and time periods, there was no difference between PQ and non-PQ groups in the low proportion of people with asexual parasites.

#### Asexual parasite clearance

Pukrittayakamee [@b12] noted no difference in parasite clearance time (Analysis 2.4).

#### Adverse effects

For haematologic adverse events, Smithuis [@b15] stated that there were no cases of severe anaemia (\< 5 g/dL) or blackwater fever in any group. [@b4] showed that there was no difference in packed cell volume between groups at day 7 (34.2% (15% to 44%) versus 36.2% (26% to 42%)) or day 14 (35.2% versus 35.4%). The difference was not significant at either day 7 (0.78, (-0.75 to 0.23), P = 0.32) or day 14 (0.86, (-0.31 to 2.0), P = 0.15). Sutanto [@b19] observed no significant difference in mean haemoglobin between groups at days 1, 8 and 43.

In Shekalaghe [@b13], although there was also no reduction in mean haemoglobin by group (Analysis 2.5), there was a significantly greater change (decrease) in haemoglobin status in the PQ group on day 8; haemoglobin decreased by 5% in the PQ group compared to 1% in the non-PQ group (Analysis 2.6). These findings suggest that rather than looking at population mean of haemoglobin, it would be more meaningful to examine the proportion of individuals who had serious adverse events: Shekalaghe [@b13] stated that 8 of 52 children in the PQ group had a 20% reduction in haemoglobin by day 8, compared to 0 of 53 children in the control group. However, Shekalaghe [@b13] also stated that no child developed clinical symptoms related to anaemia or a haemoglobin below 5 g/dL. The effect on haemoglobin in the PQ group was transient and was no longer significant by day 15.

Eziefula [@b5] used the outcome \'mean max decrease in haemoglobin\' from enrolment to day 29 and this was not significantly different between the intervention groups or with placebo. Other haematological outcomes were \'day of haemoglobin nadir\' - day 3 in all groups; maximum % decrease in haemoglobin (significantly lower in the 0.75 mg/kg group than placebo, P = 0.023) and % of patients with haemoglobin \< 50 g/L (no differences between groups). No children needed blood transfusion or had black urine or any other severe adverse events.

[@b4] assessed the minor adverse effects of vomiting, insomnia and itching and found no difference between groups. Smithuis [@b15] found a higher percentage of patients in the PQ groups had abdominal pain (16%; N = 397 versus 11%; N = 411, P = 0.05); frequencies of dizziness, nausea, anorexia, diarrhoea, palpitations, sleeplessness, headache and vomiting were not increased in the PQ groups. Sutanto [@b19] and Wang [@b18] observed no differences between groups regarding other adverse effects (Analysis 2.7).

#### Dose and schedule

***Dose of PQ:*** We stratified trials into low, medium and high dose PQ category and assessed the prevalence of gametocytes at day 8 by either microscopy or PCR (Analysis 2.8).

Only Eziefula [@b5] used a low dose category - in this case 0.1 mg/kg. There were fewer patients with gametocytes in the PQ group, but the analysis was underpowered (Analysis 2.8). Two trials used a medium dose category, with no detectable effect in one trial with few patients with PQ in the control group (Pukrittayakamee [@b12]); but with clear effect in Eziefula [@b5] with 0.4 mg/kg single dose (Analysis 2.8), and an overall effect estimate in this dose category of RR 0.34 (95% CI 0.19 to 0.59; two trials, 269 participants). The high dose category of ≥ 0.6 mg/kg reduced the prevalence of gametocytes at day 8: RR = 0.29 (0.22 to 0.37), seven trials, 1380 participants, 11 comparisons; Analysis 2.8.

***Schedule of PQ:*** We stratified this comparison into three groups: single dose on day 1 or 2, single dose day 3 or 4, and multiple doses day 1 to 7 (Analysis 2.9). This indirect comparison suggested a greater effect of single dose on days 1 to 2 than on days 3 to 4. There was only one trial of multiple doses on days 1 to 7.

### Summary analysis of gametocytes on day 8 (Comparison 3)

We have shown a single outcome, percent of participants with microscopy or PCR-detected gametocytes on day 8, for this comparison as a representative outcome across the trials. We subgrouped the data by whether or not the malaria treatment was artemisinin-based. We included only PCR data from the one trial that reported both microscopy and PCR outcomes, to avoid duplicate reporting of the same patients (Shekalaghe [@b13]).

We excluded the QN comparison of Kamtekar [@b8] because PQ was not given until day 8, but included all other trials with gametocyte outcomes (all trials except Khoo [@b9] and Wang [@b18]).

The day on which PQ was given and the gametocyte detection method varied and are presented for each trial in the footnotes in Analysis 3.1. This comparison shows that, overall, PQ reduced the prevalence of gametocytaemia on day 8 following treatment (RR 0.43, 95% CI 0.32 to 0.58, 12 trials, 2141 participants). The individual trials nearly all trended in the direction of a reduction, but an indirect comparison suggested a smaller effect for non-artemisinin-based (RR 0.63, 95% CI 0.44 to 0.88, six trials, 499 participants) than for artemisinin-based malaria treatments (RR 0.33, 95% CI 0.21 to 0.52, eight trials, 1642 participants, Analysis 3.1).

### Comparison of different 8AQ (Comparison 4)

Two small trials compared the effect of bulaquine and PQ on gametocyte prevalence at day 8 (Gogtay [@b6]; Gogtay [@b7]). Both trials suggested a greater reduction of gametocytes by bulaquine (OR 0.41 95% CI 0.26 to 0.66, two trials, 112 participants, Analysis 4.1). Neither trial concealed allocation.

ADDITIONAL SUMMARY OF FINDINGS *\[Explanation\]***PQ for reducing P. falciparum transmission with non-artemisinin-based treatmentsPatient or population:** people with symptomatic malaria**Settings:** malaria-endemic areas**Intervention:** Single dose or short course PQ plus malaria treatment which does not include an artemisinin derivative**Control:** Malaria treatment not including an artemisinin derivative, without PQ**OutcomesIllustrative comparative risks\* (95% CI)Relative effect(95% CI)Number of participants(studies)Quality of the evidence(GRADE)Assumed riskCorresponding riskControlPQMalaria incidence, prevalence or EIR**\-\--0 trials-**People infectious to mosquitoes** (day 8)**93 per 1007 per 100** (1 to 39)**RR 0.07** ^1^ (0.01 to 0.45)30(2 trials)⊕⊕⊕○ **low** ^2,3^**Participants with gametocytes on microscopy** (day 8)**Dose \< 0.4 mg/kgRR 1.76** (0.97 to 3.18)59(1 trial)⊕○○○ **very low** ^4,5,6^**33 per 10058 per 100** (32 to 105)**Dose 0.4 to 0.6 mg/kgRR 0.62** (0.50 to 0.76)283 (2 trials)⊕⊕⊕⊕ **high** ^7,8^**70 per 10043 per 100** (35 to 53)**Dose = 0.6 mg/kgRR 0.44** (0.27 to 0.70)206 (3 trials)⊕⊕⊕⊕ **high** ^9,10^**35 per 10015 per 100** (9 to 24)**Evidence of haemolysis**\--0 trials^9,10^-\*The basis for the **assumed risk** (for example, the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).**PQ:** Primaquine; **CI:** Confidence interval; **RR:** Risk ratio.GRADE Working Group grades of evidence**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.**Very low quality:** We are very uncertain about the estimate.[^15][^16][^17][^18][^19][^20][^21][^22][^23][^24]

Discussion
==========

Summary of main results
-----------------------

### PQ with artemisinin-based regimens

See Summary of findings for the main comparison..

When added to artemisinin-based therapy, a single dose of PQ above 0.4 mg/kg reduces the proportion of people with detectable gametocytaemia on day eight by around two thirds (*high quality evidence*), and can reduce the log(10) AUC estimates for gametocytaemia by up to 87.5%. However, only a single trial evaluated lower doses (0.1 mg/kg) and did not demonstrate an effect (*low quality evidence*). No trials evaluated effects on infectiousness to mosquitoes, or on malaria transmission directly (incidence, prevalence, or entomological inoculation rate).

### PQ with non-artemisinin-based regimens

See Summary of findings 2.

When added to non-artemisinin-based treatment regimens, a single dose of PQ above 0.4 mg/kg reduces the proportion of people with detectable gametocytaemia on day 8 by around a third (*high quality evidence*), and may reduce infectiousness to mosquitoes (*low quality evidence*).The single trial of lower doses (0.25 mg/kg) did not demonstrate an effect on gametocytaemia (v*ery low quality evidence*). No trials assessed effects on malaria transmission directly.

Overall completeness and applicability of evidence
--------------------------------------------------

### What is known

Adding PQ to treatment doses of artemisinin-based combination therapies appears to be an effective strategy to reduce the duration of potential infectiousness to mosquitoes (gametocytaemia). Large effects have been seen across trials from different epidemiological settings (Tanzania, Uganda, Myanmar, and Sumatra), and with different artemisinin-based treatments (AS+SP, AL, AS+AQ, AS+MQ, AS, and DHAP). Further studies evaluating this at single doses above 0.4 mg/kg are therefore probably unnecessary.

### What is unknown

While reducing the duration of gametocytaemia can be assumed to reduce infectiousness at the level of the individual, it remains unclear whether it will impact on community level transmission as reliable trials have never evaluated this. The older trials, which are often cited as proof of an effect on community transmission were excluded from this review because either: i) they lacked an adequate control group (Clyde [@b30]), ii) did not apply the interventions equally in intervention and control groups or had no \'before\' data (Doi [@b35]; Kaneko [@b46]), iii) administered PQ alongside vector control co-interventions which may equally be responsible for any effect seen (Hii [@b39]; Kaneko [@b98]), or iv) administered PQ alone and not alongside treatment regimens (which is the policy currently being considered) (Barber [@b21]).

In moderate and high transmission settings, a policy of adding PQ to malaria treatment regimens is highly unlikely to impact community transmission as most adults have a level of acquired immunity that reduces the probability that parasitaemia will cause clinical symptoms, and consequently they never seek care. These asymptomatic people are thought to represent the major source of gametocytes, and so will continue to facilitate transmission unless they are also treated with gametocytocidal drugs. Low transmission settings, especially those approaching elimination, are therefore more suited to the current policy as most people will develop symptoms following infection. However, Johnston and colleagues recently modelled the effect of PQ in low-transmission areas, and concluded that the most important factor predicting success is the percentage of infected individuals treated with an ACT, and that adding PQ is of negligible benefit (Johnston [@b97]). They estimated that \"it would require switching 180 people from ACTs to ACTs plus PQ to achieve the same transmission reduction as switching a single individual from untreated to treated with ACTs\".

Mass treatment programmes (where everyone in the community is treated at specified intervals until transmission is stopped) are a potential strategy to overcome the problem of asymptomatic gametocyte carriers (von [@b111]; GMAP [@b92]; Mendis [@b103]; Sturrock [@b110]). However, in theory, mass treatment consisting only of primary treatment (an ACT alone), would interrupt transmission, and the effects of additional PQ (interrupting transmission more quickly, or at a lower coverage levels) are unknown (Poirot [@b106]).

Perhaps even more importantly, it also remains unknown whether the current WHO-recommended dose of 0.25 mg/kg PQ has the effects seen on gametocytes with higher doses. Whilst there is some indirect evidence in narrative summaries and analyses that have proposed widespread programmatic implementation of PQ (for example, Bunnag [@b26], with no difference in gametocyte outcomes between 15 mg PQ for five days and single doses of 30 mg or 45 mg PQ in adults), the only two controlled studies which have evaluated doses below 0.4 mg/kg failed to demonstrate reliable effects. The WHO revised recommendation therefore appears to be based more on concerns about safety than on proven efficacy.

In terms of safety, it is highly likely that adverse effects in people with G6PD deficiency will be less common with lower doses of PQ. However, the evidence to reliably demonstrate this with doses 0.25 mg/kg does not currently exist. Most of the trials included in this review excluded individuals with G6PD deficiency, but in the few trials that included them no severe haematological effects have been reported. However, there are hundreds of variants of G6PD deficiency (albeit only a few that are common) and an adequate picture of how PQ affects even the common ones is lacking. Without this evidence, national malaria control programmes may remain reluctant to introduce a drug for use in population-based programmes which has the potential to harm individuals. Health professionals and programme managers around the world are aware of the association between haemolysis, G6PD deficiency and PQ and will be wary of expanded use without evidence of relative safety.

The trials included in this review do not mention PQ resistance as a potential threat. PQ clearly should be used where it is of clinical importance, especially for *P. vivax* and *P. ovale*. Its effectiveness against those parasites could be compromised by resistance if used at low doses in populations where *P. falciparum*, *P. vivax* and *P. ovale* coexist. As for all antimalarial drugs, there is a global responsibility to maintain the effectiveness of PQ for as long as possible without withholding it when needed. In this case, that translates into using it to reduce transmission only if there is reasonable evidence that it actually has that effect. Otherwise, it will be used to little or no effect but its value for radical cure may be diminished by the development of resistant *Plasmodium* parasites.

Potential biases in the review process
--------------------------------------

None known.

Agreements and disagreements with other studies or reviews
----------------------------------------------------------

In a Cochrane Review of mass drug administration (MDA) (Poirot [@b106]), the authors found no studies directly comparing MDA regimens that included 8AQs with regimens that did not. In a secondary analysis, the authors then subgrouped included non-randomized controlled trials by regimens with and without 8AQs. In high endemicity areas, two studies included PQ, and one study did not. During multiple MDA rounds, there were substantial drops in parasitaemia regardless of whether PQ was included. At 1 to 3 months, the studies without PQ showed larger impact than the one study that did, but this single observation from a non-randomized comparison cannot be relied upon. In a second similar subgroup analysis of four before and after studies, the stratified analysis was uninformative.

In an opinion piece in the Lancet, the possibility that doses lower than 0.5 to 0.75 mg/kg might still be very effective in blocking transmission is raised (White [@b115]). Based on the current review, however, there is insufficient information to know whether the effect is preserved with doses of less than 0.4 mg/kg.

A review in the *Malaria Journal* provides an analysis of published and unpublished data on 158 subjects with different drug exposures spanning 80 years (White [@b114]). The methods and sources of data are not clearly specified, but the authors argue this provides evidence that PQ decreases infectivity much faster than the effect on gametocytes would suggest. Our review identified very limited data from controlled studies testing the effect of PQ on infectiousness to mosquitoes (2 trials, with 30 participants, in people given non-artemisinin treatments), so was not able to confirm or refute this early effect on gametocyte viability.

A paper whose title implies it was a systematic review of the impact of artemisinin derivatives and PQ on infectiousness (Abay [@b76]) included only two before-and-after trials using PQ with small numbers of patients. Neither of these studies met our inclusion criteria (Rieckmann [@b54]; Clyde [@b32]). A historical review of patients treated at clinics in India with either AS+SP+PQ (single dose 0.75 mg/kg on the third treatment day, nine sites) or AS+SP alone (12 sites) observed that PQ reduced the gametocyte clearance time by 45% and the AUC of gametocyte density over time (up to 28 days) by about the same proportion (Shah [@b57]). They expressed the reduction as a hazard ratio with PQ increasing the rate of gametocyte clearance by 1.9 (95% CI 1.1 to 1.3). These results are consistent with our findings.

In relation to current WHO guidelines, no direct evidence was available to include in this systematic review to support the currently recommended 0.25 mg/kg dose as effective in reducing transmission either from individuals or in communities (WHO [@b118]). Ongoing studies may help inform this current gap in our knowledge (Eziefula [@b91]).

Authors\' conclusions
=====================

Implications for practice
-------------------------

Current policy recommendations that 0.25 mg/kg PQ should be added as a single dose to primary treatment for *P. falciparum* malaria in areas that are targeting elimination or are facing artemisinin resistance are based on judgements and inferences rather than reliable evidence of an effect at this dose.

Decisions must be specific to the country or area where the introduction is being considered. In a high endemicity area, the dilutional effects are likely to be important. If PQ is given as part of clinical treatment in a low endemicity area, what might be important is whether most people with parasitaemia are likely to be seen at clinic. Thus the evidence presented in this review is likely to be used to lead to different decisions depending on a variety of epidemiological, malarial and logistic factors.

Whilst harm at the currently recommended dose of 0.25 mg/kg is likely to be much less than at higher doses, these trials are insufficient to evaluate whether the drug is safe (for widespread use) at any dose.

Implications for research
-------------------------

Future RCTs of low dose PQ should include measures of infectiousness to mosquitoes over an extended period including the days immediately following treatment, and stratify the analysis by participants with and without gametocytes at baseline.

The impact on individuals with G6PD deficiency (an agreed upon set of the most widespread genotypes and those with the greatest likelihood for harm) should be assessed.

Given the high frequency of asymptomatic infections, information on individual patients should be combined with modelling or community-based trials of treatment regimens with and without PQ to determine the malaria and population characteristics under which PQ is likely to be an important additional contributor to malaria elimination programmes (including mass treatment and \'test and treat\').
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Appendix 1. Search strategy
===========================

Search setCIDG SR^1^CENTRALMEDLINE^2^EMBASE^2^LILACS^2^**1**malariaMALARIA, FALCIPARUM/ DRUG THERAPYMALARIA, FALCIPARUM/ DRUG THERAPYMALARIA FALCIPARUM/DRUG THERAPYMalaria AND falciparum**2**primaquine OR pamaquine OR plasmoquine OR plasmochin OR plasmocide OR rhodoquine OR plasmocid OR quinocine OR pentaquine OR isopentaquine OR bulaquine OR tafenoquine OR 8-aminoquinoline\*Malaria AND falciparum ti, abMalaria AND falciparum ti, abMalaria AND falciparum ti, abprimaquine OR pamaquine OR plasmoquine OR plasmochin OR plasmocide OR rhodoquine OR plasmocid OR quinocine OR pentaquine OR isopentaquine OR bulaquine OR tafenoquine OR 8-aminoquinoline\$**3**1 and 21 or 21 or 21 or 21 and 2**4**-PRIMAQUINE/ ADMINISTRATION AND DOSAGE/ THERAPEUTIC USEPRIMAQUINE/ ADMINISTRATION AND DOSAGE/ THERAPEUTIC USEPRIMAQUINE-**5**-primaquine OR pamaquine OR plasmoquine OR plasmochin OR plasmocide OR rhodoquine OR plasmocid OR quinocine OR pentaquine OR isopentaquine OR bulaquine OR tafenoquine OR 8-aminoquinoline\* ti, abprimaquine OR pamaquine OR plasmoquine OR plasmochin OR plasmocide OR rhodoquine OR plasmocid OR quinocine OR pentaquine OR isopentaquine OR bulaquine OR tafenoquine OR 8-aminoquinoline\* ti, abprimaquine OR pamaquine OR plasmoquine OR plasmochin OR plasmocide OR rhodoquine OR plasmocid OR quinocine OR pentaquine OR isopentaquine OR bulaquine OR tafenoquine OR 8-aminoquinoline\* ti, ab-**6**-4 or 54 or 54 or 5-**7**-3 and 63 and 63 and 6-**8**\--Limit 7 to HumansLimit 7 to Human-[^25][^26]

CHARACTERISTICS OF STUDIES
==========================

Characteristics of included studies *\[ordered by study ID\]*
-------------------------------------------------------------

Arango 2012MethodsQuasi-RCT: alternate allocation to AQ+SP and AQ+SP+PQ, then MQ+AS and MQ+AS+PQParticipantsInclusion criteria: 1. Uncomplicated malaria 2. Pf only 3. Not pregnant 4. Voluntary consent Colombia 82 patients, aged one to 75 years (mean age ranged from 24 to 35 years in four groups) Gametocytes in 23/82 (28%)InterventionsAll loose combinations 1. AQ+SP 2. AQ+SP+PQ 3. MQ+AS 4. MQ+AS+PQ AQ: 25 mg/kg total dose divided into 10 mg/kg on day 1 and 7.5 mg/kg on days 2 and 3 SP: 25 mg/kg/1.25 mg/kg single dose on day 1 MQ: 25 mg/kg total dose, divided into 8.3 mg/kg per day for 3 days AS: 4 mg/kg per day for 3 days PQ: 0.75 mg/kg, total single dose on day 2OutcomesDay 1 (pretreatment with schizonticide), 4, and 8 Asexual and gametocyte counts in thick smears Gametocyte prevalence Gametocyte densityNotesNo mention of G6PD status***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskAlternate allocation.Allocation concealment (selection bias)Unclear riskNot discussed.Incomplete outcome data (attrition bias) All outcomesLow riskNo evidence of incomplete data.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasUnclear riskNothing obvious.Blinding of participants and personnel (performance bias) All outcomesUnclear riskNot discussed.Blinding of outcome assessment (detection bias) All outcomesUnclear riskNot discussed. Chen 1993aMethodsRCTParticipants18 participants with *P. falciparum*InterventionsA: MQ 750 mg B: MQ 750 mg + SP (1500 mg/75 mg) C: MQ 750 mg + PQ 45 mg All single doses Follow-up: 28 days for gametocytes and 21 days for infectiousnessOutcomesGametocyte prevalence at days 3, 8, 14, and 21 Infectiousness to *An. dirus* Sporozoite infections in mosquitoes Infectivity of sporozoite-infected mosquitoes to subsequent patientsNotesOnly abstract available. Mosquitoes fed on the patients were allowed to develop sporozoites which were then fed on uninfected people. One of the MQ + PQ group passed the infection to a new person.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskTrial authors stated it was randomized in abstract.Allocation concealment (selection bias)Unclear riskNo information in abstract.Incomplete outcome data (attrition bias) All outcomesLow riskAll patients were followed up.Selective reporting (reporting bias)Unclear riskNo information in abstract.Other biasUnclear riskNone known.Blinding of participants and personnel (performance bias) All outcomesLow riskStated to be double blind in title.Blinding of outcome assessment (detection bias) All outcomesUnclear riskNo information in abstract. Chen 1994MethodsPossibly individually RCT (stated to be randomized but no information given). Dates of trial not reported.Participants27 patients with slide positive *P. falciparum* including both asexual stages and gametocytes. No information given on age or sex. All dosages appear to be adult dosages. Site: malaria-endemic Hainan Island, China. Exclusion criteria: history of antimalarial treatment for present attack.Interventions1. Artemisinin: 1200 mg per day for 5 days (not included in review). 2. MQ 750 mg single dose day 1 (reported as day 0). 3. MQ 750 mg single dose + PQ 45 mg single dose day 1 (reported as day 0).Outcomes1. Gametocyte density: days 5, 8, 15, 22, and 29 (reported in paper as days 4, 7, 14, 21, and 28 since first day was day 0). Given as % of initial density on chart only. 2. Percentage of participants infectious to *An. dirus:* days 5, 8, 15, and 22 (reported as days 4, 7, 14, and 21). 3. Percentage of mosquitoes infected: days 5, 8, 15, and 22 (reported as days 4, 7, 14, and 21).NotesFor gametocyte density, graph only of percentages; no raw numbers given except range of asexuals and gametocyte numbers reported for each group on day 1 (reported as day 0).***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNo information on sequence generation. Trial authors described process as participants \"divided into groups A, B, and C\". Equal number in each group and lack of detail suggests randomization not done adequately.Allocation concealment (selection bias)High riskNo data to suggest any measures to conceal allocation.Incomplete outcome data (attrition bias) All outcomesLow riskNo missing participants in intervention groups 2 and 3.Selective reporting (reporting bias)Low riskNo obvious selective reporting.Other biasLow riskNo indication of other bias.Blinding of participants and personnel (performance bias) All outcomesUnclear riskNot reported.Blinding of outcome assessment (detection bias) All outcomesUnclear riskNot reported. El-Sayed 2007MethodsIndividually RCT Dates of trial: Randomization June 2004; trial done 17 August 2004 to 3 September 2004.Participants104 people with asymptomatic *P. falciparum* positive by slide and positive for gametocytes by PCR. No information given on age and sex. Site: Two villages in East Sudan where there is seasonal malaria, mainly *P. falciparum,* during October to December. Exclusion criteria: pregnancy, history of sulfa allergy, fever or other symptoms, *Plasmodium* spp other than *P. falciparum* present.Interventions1. AS: Children \< 50 kg: 4 mg/kg; All = 50 kg: 200 mg (two 100 mg tabs) days 1, 2, and 3 (reported as days 0, 1, and 2). SP: Children \< 50 kg: 25 mg/kg S + 1.25 mg/kg P; All = 50 kg: 3 tablets of 500 mg S + 25 mg P. 2. As for 1. above plus PQ 0.75 mg/kg day 4 (reported as day 3).Outcomes1. Proportion of people with *P. falciparum* parasites by PCR days 4, 8 and 15 (reported as days 3, 7 and 14). 2. Proportion of people with gametocytes by RT-PCR days 8 and 15 (reported as days 7 and 14). 3. Adverse events days 2, 3, 4, 8 and 15 (reported as days 1, 2, 3, 7 and 14). 4. Packed cell volume days 1, 8 and 15 (reported as days 0, 7 and 14).NotesThe trial was conducted about two months after the initial screening for positives (asymptomatic carriers).***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low risk\"The list of carriers was sorted according to village and age to ensure that the treatment groups were balanced with respect to these two variables. The random allocation of this ordered list into the treatment arms was then created using restricted randomization with a block size of 12 in STATA v7\"Allocation concealment (selection bias)Unclear riskNo information given.Incomplete outcome data (attrition bias) All outcomesLow riskOnly three of 104 participants did not complete follow-up.Selective reporting (reporting bias)Low riskNo obvious selective reporting.Other biasLow riskNo indication of other bias.Blinding of participants and personnel (performance bias) All outcomesHigh riskPatients and health staff were not blinded.Blinding of outcome assessment (detection bias) All outcomesLow riskLab staff doing PCR were blinded. Eziefula 2013MethodsIndividually randomized placebo-controlled, double blind trial conducted December, 2011 to March, 2013Participants468 randomized, aged one to 10 years old, male and female Inclusion criteria: 1. *P. falciparum* mono infection with parasite density lower than 500000 parasites/μL 2. Normal G6PD enzyme function 3. Fever or history of fever in past 24 hours Exclusion criteria: 1. Signs of severity 2. Haemoglobin concentration \< 80 g/L 3. Known allergy to the trial drugs 4. Antimalarials taken within the past two days 5. PQ taken within the past four weeks 6. Blood transfusion within the past 90 daysInterventions1. AL standard three day (twice per day) course + placebo (given with 5th AL dose, ie, with 1st dose on 3rd day of treatment) 2. AL + 0.1 mg/kg PQ 3. AL + 0.4 mg/kg PQ 4. AL + 0.75 mg/kg PQ (reference)OutcomesPrimary efficacy: Mean duration of gametocyte carriage Secondary efficacy: Point prevalence of gametocytes on days 7, 10, and 14; gametocyte circulation time (days), AUC of gametocyte density Primary safety: Arithmetic mean maximum decrease in haemoglobin concentration from enrolment to day 28 Secondary safety: Day of haemoglobin nadir, maximum percentage decrease in haemoglobin, percentage of participants with haemoglobin concentration lower than 50 g/L, requirement for blood transfusion, evidence of black urine, and frequency of severe adverse events.NotesG6PD enzyme function based on a fluorescence spot test (R&D Diagnostics, Aghia Paraskevi, Greece)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer-generated four-digit treatment assignment codes and allocated these to random dose groups in block sizes of 16.Allocation concealment (selection bias)Low riskOnly the pharmacist was aware of allocation.Incomplete outcome data (attrition bias) All outcomesLow riskOnly 8% of patients were lost to follow-up. No group significantly different from others.Selective reporting (reporting bias)Low riskNone detected or suspected.Other biasLow riskNone detected or suspected.Blinding of participants and personnel (performance bias) All outcomesLow risk\"Masking syrup\" added to all treatments to mask taste of drug.Blinding of outcome assessment (detection bias) All outcomesLow riskAssessors were blinded. Gogtay 2004MethodsAllocated by \"simple, computer-generated randomization code\"ParticipantsTwenty-two patients in Mumbai, India Inclusion criteria: 1. = 18 years 2. normal G6PD 3. = 55 *P. falciparum* gametocytes/μL on admission Exclusion criteria: 1. Complicated malariaInterventions1. Quinine days 1 to 7: 30 mg/kg/day + PQ (45 mg) 2. Quinine days 1 to 7: 30 mg/kg/day + bulaquine (approximately 75 mg base)OutcomesAsexual and gametocyte counts on days 1, 4, 8, 15, 22 and 29 Adverse eventsNotes***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer-generated randomization.Allocation concealment (selection bias)Unclear riskNot reported.Incomplete outcome data (attrition bias) All outcomesLow riskNo evidence of incomplete data.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasHigh riskUnbalanced allocation (9 versus 13) and small number of participants.Blinding of participants and personnel (performance bias) All outcomesUnclear riskNot reported.Blinding of outcome assessment (detection bias) All outcomesLow riskLaboratory technician reading blood smears was blinded. Gogtay 2006MethodsRandomized (computer-generated) to PQ or bulaquine (1:2 ratio) after primary treatment with quinine + doxycyclineParticipants93 participants in India Inclusion criteria: 1. = 16 years 2. Male 3. Uncomplicated Pf only 4. = 55 *P. falciparum* gametocytes/μL on admission Exclusion criteria: 1. Antimalarial treatment in previous two weeks 2. Allergy to trial drug 3. G6PD deficientInterventionsAll patients: Quinine days 1 to 7: 30 mg/kg/day (10 mg/kg/day three times per day) + 100 mg doxycycline Randomization and treatment on day 4 1. PQ 2. BulaquineOutcomesGametocyte prevalence, density and viability on days 1, 4, 15, 22 and 29 Adverse eventsNotesGametocyte viability assessed by Shute\'s technique (exflagellation)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer-generated randomization.Allocation concealment (selection bias)Unclear riskNot reported.Incomplete outcome data (attrition bias) All outcomesLow riskNo evidence of incomplete data. Three participants (two bulaquine, one PQ) did not return for follow-up.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNone noted.Blinding of participants and personnel (performance bias) All outcomesUnclear riskNot reported.Blinding of outcome assessment (detection bias) All outcomesLow riskSlide readers were blinded. Kamtekar 2004MethodsIndividually RCT, comprising two distinct comparisons a: (CQ or \[CQ+SP\]) with and without PQ and b: QN with and without PQ. Dates of trial: not given.Participants57 people aged ≥ 16 years with symptomatic uncomplicated and 46 with severe (WHO criteria) *P. falciparum* malaria, diagnosed by thick and thin blood slides. Gametocytaemic within first 72 hrs with = 55 *P. falciparum* gametocytes/μL Site: urban areas of Mumbai, India. Exclusion criteria: Pregnant or lactating, treatment for malaria within last two weeks, co-infection with *P.vivax*, history of PQ allergy.InterventionsComparison a: for uncomplicated malaria All received CQ (some also got SP) Day 4: randomized to PQ or placebo (45 mg) Comparison b: for severe malaria All received quinine Day 8: randomized to PQ or placebo (dose 45 mg) Doses background drugs: CQ 10 mg/kg on days 1 and 2; 5 mg/kg on day 3; SP 1500 mg; quinine dose 10 mg/kg every 8 hrs for 24 to 48 hrs and orally for total of 7 daysOutcomes1. Proportion of people with gametocytes, days 1, 4, 8, 15, 22, 29. 2. Proportion of people with viable gametocytes (exflagellation), days 1, 4, 8, 15, 22, 29. 3. Gametocyte density (given as range) days 1, 4, 8, 15, 22, 29.NotesNo screening for G6PD deficiency. It is not stated how many got SP in addition to CQ or why.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High risk\"simple computer generated randomization code\". Not all patients had gametocytes on day 1. Inclusion criteria were that the person had to have gametocytes in the first 72 hours (from day 1?). This suggests some post randomization inclusions or exclusions.Allocation concealment (selection bias)Unclear riskNo information.Incomplete outcome data (attrition bias) All outcomesHigh riskOriginally there were 57 people included in uncomplicated comparison (a), of whom 2 were lost to follow-up and 9 were not evaluated as they showed CQ resistance. There were 46 in severe comparison (b), of whom 3 were lost to follow-up. The final numbers evaluated in each group were (a) 22 and 24 (b) 22 and 21.Selective reporting (reporting bias)Unclear riskNo obvious selective reporting.Other biasHigh riskIt was not clear why some patients got SP and others did not, and the numbers in each group are not given.Blinding of participants and personnel (performance bias) All outcomesLow riskTrial used a placebo for PQ. Patients and health workers were blinded.Blinding of outcome assessment (detection bias) All outcomesLow riskSlide readers were blinded. Khoo 1981MethodsIndividually RCT Dates of trial: between June 1976 and March 1978.Participants69 people (adults and children of both sexes, no ages specified) with G6PD deficiency (full or partial by Brewer\'s methaemoglobin reduction test) who were slide positive for malaria (*P. falciparum*, *P. vivax* or mixed). Site: Sabah, Malaysia. Exclusion criteria: other associated clinical conditions.Interventions1. CQ: 1.5 g CQ over 3 days for *P. falciparum*, *P. vivax* or mixed, less for children 2. CQ + PQ: CQ as above plus 75 mg PQ over 3 days for *P. falciparum*; 210 mg PQ over 14 days for *P. vivax* and mixed infections; less for children 3. SP (not included in this review): 1.5 g S and 75 mg P, single doseOutcomes1. Haemolysis 2. Proportion cleared parasites by 72 hours 3. Need for blood transfusion 4. Renal failureNotesThe participants are not divided by *P. falciparum*, *P. vivax* or mixed, so it is not possible to use the data.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"those found G6PD deficient were randomly assigned\".Allocation concealment (selection bias)Unclear riskNo information given.Incomplete outcome data (attrition bias) All outcomesUnclear riskNo information given.Selective reporting (reporting bias)Low riskNo apparent selective reporting.Other biasLow riskNo indication of other bias.Blinding of participants and personnel (performance bias) All outcomesUnclear riskNot reported.Blinding of outcome assessment (detection bias) All outcomesUnclear riskNot reported. Kolaczinski 2012MethodsIndividually RCT Dates of trial: between July and January, from 2000 to 2003.Participants237 individuals aged from 3 to 70 years, in 5 villages for Afghan refugees in Pakistan. Inclusion: = 2 years of age, *P. falciparum* mono-infection, confirmed by slide, will be resident during entire follow-up period. Exclusions: pregnancy, signs of severe malaria, report of antimalarial drug in past 21 days, other serious diseaseInterventions1. CQ: 3 days 25 mg/kg. 2. CQ+PQ: CQ as in 1; PQ on day 3 (0.5 mg/kg). 3. SP: 25(S)/1.25(P) mg/kg in single dose. 4. SP+PQ: SP as in 3; PQ on same day (0.5 mg/kg).Outcomes1. Clinical treatment failure (PCR non-adjusted and adjusted). 2. Gametocytes on day 8. 3. Gametocyte density on days 1 to 8 of follow-up. 4. Genotyping of resistant strains for CQ and SP-specific mutations.NotesAlso included CQ + AS and SP + AS arms, compared with CQ +/- PQ and SP +/- PQ arms, respectively.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskPatients numbered sequentially at enrolment. Random numbers with treatment assignment from Excel-generated lists, then paired with patient numbers.Allocation concealment (selection bias)Low riskPatient number concealed until after enrolment.Incomplete outcome data (attrition bias) All outcomesLow risk209 of 237 randomized completed treatment and at least one follow-up test. 47 (13%) of those randomized did not contribute data. Variable numbers tested during follow-up (see analyses).Selective reporting (reporting bias)Low riskNone detected.Other biasLow riskNone noted.Blinding of participants and personnel (performance bias) All outcomesHigh riskIdentified in report as \'single-blind\'. Manager (gave Rx) not blinded; patients, microscopists and health workers \'partially blinded\' due to different drug appearance and times of follow-up. No placebos used, but vitamin given to those in non-PQ arms.Blinding of outcome assessment (detection bias) All outcomesLow riskImplied only. Ledermann 2006MethodsIndividually RCT Date of trial: July to Oct 2001.Participants117 malaria cases with *P. falciparum* ≥ 400 asexual stages/μL (thick film) recruited by mass blood survey and passive case detection. Symptoms not required. Age: ≥ 15 years Site: Central Java, Indonesia, an area with high CQ resistance and resurgent malaria approximately equal *P. falciparum* and *P. vivax*. Exclusion criteria: Pregnancy, breast feeding, body weight \< 40kg, G6PD deficiency, history of antimalarial or antibiotic in last seven days, severe or complicated malaria, history or allergy or adverse reaction to trial medications, Pv or mixed infection.Interventions1. CQ only (not included in this review). 2. CQ+SP: CQ 150 mg base, 10, 10 and 5 mg/kg on days 1, 2, 3 (reported as days 0, 1, 2). SP 500 mg S 25 mg P on day 1 (reported as day 0). 3. CQ+SP as for group 2 above plus PQ 45 mg on day 1 (reported as day 0). 4. CQ+SP as for group 2 above plus PQ 45 mg on day 3 (reported as day 2).Outcomes1. Parasite clearance time assessed at days 1, 3, 8, 15, 22, 29 or day of recurrent parasitaemia (reported as days 0, 2, 7, 14, 21, 28). 2. Fever clearance time at days 2, 3, 4, 5, 8, 12, 15, 19, 22, 29. 3. Proportion of people with gametocytes (from chart) days 1 to 29. 4. Adverse events.NotesSome comparisons in the results reported include the CQ only group.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskTrial subject codes were assigned to treatment arms by a random process (not specified).Allocation concealment (selection bias)High riskEligibles were assigned a sequential participant number by the screening physician. Pre-packaged treatment but not stated whether allocation was concealed.Incomplete outcome data (attrition bias) All outcomesLow risk7% of participants withdrew before day 28.Selective reporting (reporting bias)Unclear riskAbstract states that drugs were well tolerated and safe but no evidence is given in report.Other biasLow riskNo indication of other bias.Blinding of participants and personnel (performance bias) All outcomesUnclear riskBlinding was implied only.Blinding of outcome assessment (detection bias) All outcomesUnclear riskBlinding was implied only. Pukrittayakamee 2004MethodsIndividually RCT Dates of trial not stated.Participants176 patients with acute uncomplicated *P. falciparum*. After exclusion of QN+tetracycline group: 146. Age 14 to 62. All male. Site: Hospital for Tropical Diseases, Bangkok, Thailand. Exclusion criteria: Severe malaria, mixed malaria infection, history of drug hypersensitivity, any antimalarial within last 48 hrs, urine positive for sulfonamide or 4AQ. People with G6PD deficient phenotype were excluded from receiving PQ.Interventions1. QN: QN sulfate (300 mg salt/tab) at 10 mg salt/kg, three times per day for 7 days. 2. QN+tetracycline (excluded from this review). 3. QN+PQ low dose: QN as above in 1 plus PQ 15 mg base/tab, 0.25 mg/kg base (adult dose 15 mg base) daily for 7 days. 4. QN+PQ high dose: QN as above in 1 plus PQ 0.50 mg/kg base (adult dose 30 mg base) daily for 7 days. 5. AS: AS 50 mg salt/tab 3.3 mg/kg (adult dose 200 mg) on day 1 and 1.65 mg/kg (adult dose 100 mg) daily on days 2 to 7. 6. AS+PQ (high dose): AS as above plus PQ 0.5 mg/kg base daily on days 1 to 7.Outcomes1. Parasite clearance time: measured at 12 hrs until clearance. 2. Gametocyte clearance time: median, 12 hrs until clearance. 3. Fever clearance time (measured every 4 hr at first and then every 6 to 12 hrs until resolution of fever). 4. Parasite reduction ratio at 48 hrs. 5. Reappearance of infection *P. falciparum*/*P. vivax* up to 28 days. 6. Prevalence of gametocytes on admission/after treatment/total. 7. Gametocyte carriage: total number of hours for which gametocytes were detectable.NotesPatients with recrudescence of *P. falciparum* or relapse of *P. vivax* were re-treated with 7 day QN+tetracycline or \'standard doses\' of CQ+PQ respectively; not clear if they were excluded from further trial.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskMethod not stated. Patients with G6PD deficiency were excluded from getting PQ which suggests randomization was biased.Allocation concealment (selection bias)Unclear riskNo information given.Incomplete outcome data (attrition bias) All outcomesUnclear risk122/142 of the original participants in the 5 groups studied here completed follow-up. Patients with recrudescences of *P. falciparum* or relapse of *P. vivax* were re-treated with QN+tetracycline or CQ+PQ respectively; not clear if they were excluded from further trial.Selective reporting (reporting bias)Unclear riskNot detected.Other biasUnclear riskThose who were unable to stay in hospital until clearance of both fever and parasites were excluded from trial of fever clearance time.Blinding of participants and personnel (performance bias) All outcomesUnclear riskNot reported.Blinding of outcome assessment (detection bias) All outcomesUnclear riskNot reported. Shekalaghe 2007MethodsIndividually RCT Dates of trial: June to Sept 2006.Participants108 children with fever = 37.5 °C or history of fever in last 48 hours and *P. falciparum* mono-infection 500 to 100,000/μL. Age three to 15 years. Both sexes. Site: Mynuzi health center, NE Tanzania, a hyperendemic area with rainy seasons in Mar-June and Oct-Dec. Exclusion criteria: Hb \< 8, inability to take drugs orally, known hypersensitivity to meds, reported anti-malarial treatment in last two weeks, evidence of chronic disease or acute infection other than malaria, domicile outside trial area, signs of severe malaria, eligible for other malaria studies.Interventions1. AS+SP: AS: 4 mg/kg once daily for 3 days; SP: S 25 mg/kg and P: 1.125 mg/kg 2. AS+SP+PQ: As above for AS and SP plus PQ base 0.75 mg/kg on the third day.Outcomes1. Proportion of people with gametocytes (by microscopy) days 1, 4, 8, 15, 29, and 43 (reported as 0, 3, 7, 14, 28, and 42). 2. Proportion with gametocytes (by PCR), same time points. 3. Gametocyte density by PCR. 4. AUC for gametocyte presence. 5. Adverse events. 6. Adequate clinical and parasitological response. 7. Haemoglobin.NotesHb outcome assessed with respect to G6PD variant.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskGenerated in STATA 8.0 using restricted randomization with block size of 20.Allocation concealment (selection bias)Unclear riskPre-prepared envelopes (but person who opened envelope administered treatment).Incomplete outcome data (attrition bias) All outcomesLow riskOnly 2 out of 108 failed to complete follow-up.Selective reporting (reporting bias)Low riskNo information given.Other biasLow riskNo indication of other bias.Blinding of participants and personnel (performance bias) All outcomesUnclear riskTrial physician evaluated patients, opened envelopes, and administered treatment. Other staff were blinded. Not clear if participants were blinded.Blinding of outcome assessment (detection bias) All outcomesUnclear riskNot stated. Singhasivanon 1994MethodsIndividually RCT Dates of trial: not stated.Participants23 people with uncomplicated *P. falciparum* malaria, parasitaemia between 1-5 per 1000 rbc. Age five to 12 years, sex not stated. Exclusion criteria: antimalarial drugs, urine with quinoline and sulfonamide drugs, other diseases, hematocrit ≤ 20%, inability to take oral medication.Interventions1. MSP: MQ 20 mg/kg; S 40 mg base/kg; P 2 mg/kg; single dose. 2. MSP + PQ: As above plus PQ 0.75 mg/kg single dose. MSP+PQ crushed and mixed with 30 ml syrup (83% dextrose).Outcomes1. Gametocyte clearance time (days) (assessed twice daily until negative, then once daily, by blood slide). 2. Adverse drug reactions, assessed once daily in first week then once a week. 3. Parasite clearance time (hrs). 4. Fever clearance time (hrs). 5. Cure rate.NotesThose who vomited within three hours of Rx were excluded - this is a post randomization exclusion.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNo information given.Allocation concealment (selection bias)Unclear riskNo information given.Incomplete outcome data (attrition bias) All outcomesHigh riskOutcomes only reported for 18 of the 23 participants.Selective reporting (reporting bias)Unclear riskNo information given.Other biasHigh riskThose who vomited within three hours of Rx were excluded- this is a post randomization exclusion.Blinding of participants and personnel (performance bias) All outcomesUnclear riskNot stated.Blinding of outcome assessment (detection bias) All outcomesUnclear riskNot stated. Smithuis 2010MethodsIndividually RCT (5 comparisons - 10 arms). Follow-up: Patients were asked to return weekly for 9 weeks for assessment and at any other time they were unwell. Dates: Dec 2008 to March 2009.ParticipantsNumber: 808 people attending clinics in Myanmar. Inclusion criteria: Age = 6 months, weight = 5 kg, *P. falciparum* mono-infection 500 to 200,000 parasites/µL or co-infection with *P. vivax*, informed consent. Exclusion criteria: Pregnancy, signs of severe malaria, severe malnutrition, history of hypersensitivity to any of the trial drugs, severe malnutrition, concomitant febrile illness, history of psychiatric disorder, a full course of MQ in the previous nine weeks or any other antimalarial in the previous 48 hrs.InterventionsEach of the five trial arms was divided into two where one half also received a one-off dose of 0.75 mg/kg PQ on day 1. Groups: 1+2. AS plus amodiaquine, fixed-dose combination: 25 mg/67.5 mg or 50 mg/135 mg or 100 mg/270 mg tablets. • AS 4 mg/kg once daily for 3 days • AQ 10.8 mg base/kg once daily for 3 days 3+4. AL, fixed-dose combination: 20 mg/120 mg tablets. • A 3.3 mg/kg in two divided doses each day for 3 days • L 19.8 mg/kg in two divided doses each day for 3 days • Advised to consume fatty food or breast feed before each dose 5+6. AS plus MQ, fixed-dose combination: 25 mg/55 mg or 100 mg/220 mg tablets (artesunate: Guilin, Lariam: Hoffman-La Roche) • AS 4 mg/kg once daily for 3 days • MQ 8.8 mg/kg once daily for 3 days 7+8. Artesunate plus MQ, loose combination (artesunate: Guilin, Lariam: Hoffman-La Roche) • AS 4 mg/kg once daily for 3 days • MQ 25 mg base/kg as a single dose on day 1 (reported as day 0) 9+10. DHAP, fixed-dose combination: 40 mg/320 mg or 20 mg/160 mg tablets (Artekin: Holleykin) • DHA 2.5 mg/kg once daily for 3 days • P 20 mg/kg once daily for 3 days First dose supervised, all others unsupervised.Outcomes1. Recurrent parasitaemia at day 15, 29, 43 and 64 (reported as days 14, 28, 42 and 63). 2. Treatment failure due to *P. falciparum.* 3. Gametocytaemia prevalence. 4. Person-gametocyte weeks. 5. Haemoglobin on days 1 and 64. 6. Adverse events (monitoring not described).NotesFunding: Médecins sans Frontières (Holland).***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low risk\"After patients were screened and enrolled in the study, they were stratified prospectively into three age groups (1 to 4 years, 5 to 14 years and older than 14 years). Patients were randomly assigned in equal numbers to receive one of the five different treatments. They were then randomly assigned either a single dose of PQ ... or not\".Allocation concealment (selection bias)Low risk\"Treatment allocations were put in sealed envelopes in blocks of 50 for each age group, and random assignment was achieved by patients drawing an envelope from a box after enrollment. When the box was empty, another 50 envelopes were added\".Incomplete outcome data (attrition bias) All outcomesLow riskAttrition is low in absolute numbers and unlikely to have introduced significant bias.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo indication of other bias.Blinding of participants and personnel (performance bias) All outcomesHigh riskOpen label trial for patients and medical staff.Blinding of outcome assessment (detection bias) All outcomesLow riskMicroscopists were blinded. Sutanto 2013Methods2-arm open-label RCT Follow-up: days 1, 2, 3, 7, 14, 21, 28, 35 and 42, and any other day in between if they felt ill. Thin and thick blood smears and dried blood spot for genotyping Dates of randomization: December 2008 to March 2010Participants188 (178 left on day 3) + 186 (171 day 3). Analysis based on those still present on day 3 Setting: Hanura Primary Health Center, Padang Cermin district, Lampung province located at the southern end of Sumatra. Endemicity: low malaria endemicity with a malaria prevalence of 1.8% across all age groups. Seasonal transmission. Inclusion criteria: (1) parasite density ≥ 1000 parasites/μL; (2) age ≥ 5 years; (3) normal glucose-6-phosphate dehydrogenase (G6PD) enzyme levels based on a qualitative test; (4) haemoglobin level ≥ 8 g/dL; (5) negative pregnancy test (assessed by human chorionic gonadotropin urine test) or not breastfeeding; (6) no signs of severe malnutrition; (7) no other chronic diseases; (8) no history of allergy to the trial drugs; (9) ability to return for 42 days of follow-up.Interventions1. Standard 3-day DHAP (fixed-dose tablets of 40 mg dihydroartemisinin and 320 mg piperaquine; D-ARTEPP, Guilin Pharmaceutical Co, Ltd) 2. DHAP as in intervention 1; PQ: Day 3, single dose of 0.75 mg/kg, rounded to the nearest half tablet. Mean dose was 0.74 mg/kg (range, 0.5 to 0.94 mg/kg)Outcomes1. Gametocyte prevalence-days 7, 14, 21, 28, 35, and 42 2. Gametocyte clearance rates by day 42 in patients with gametocytes on day 3, 3. Recurrence of asexual stages of *P. falciparum*, polymerase chain reaction (PCR) adjusted and unadjusted for reinfections. 4. Gametocyte development by day 42 in patients who were gametocyte free on day 3. 5. Gametocyte densities between days 3 and 42 inclusive. 6. Asexual infection recurrence by PCR. 7. Hemoglobin on days 7, 42. 8. Adverse events.Notes***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer-generated sequences in blocks of four.Allocation concealment (selection bias)Low riskOpaque envelopes used in order at the health centre.Incomplete outcome data (attrition bias) All outcomesLow riskNo evidence of differential attrition.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNone detected.Blinding of participants and personnel (performance bias) All outcomesHigh riskNo blinding, no PQ placebo.Blinding of outcome assessment (detection bias) All outcomesUnclear riskNo information. Vasquez 2009MethodsIndividually RCT Dates of trial: April 2007 to Feb 2008.Participants50 people with uncomplicated *P. falciparum* diagnosis by thick blood slide, 150 to 50,000 parasites/μL Age one year and over, both sexes. Exclusion criteria: pregnant, mixed infection, danger signs and complications, allergy to antimalarials, serious illness at time or presentation, antimalarial treatment in last 72 hrs, MQ in last four weeks.Interventions1. AS+MQ Age 1 to 6: AS 50 mg on days 1, 2, 3 (reported as 0, 1, 2); MQ 250 mg on day 2. Age 7 to 13: AS 100 mg on days 1, 2, 3, MQ 250 mg on days 1, 2, 3. Age = 13: AS 200 mg on days 1, 2, 3, MQ 500 mg on days 1, 2, 3. 2. AS+MQ+PQ As above plus PQ: Age 1 to 6: 0.3-0.6 mg/kg day 3 (reported as day 2). Age 7 to 13: 22.5 mg/kg day 3. Age = 13: 45 mg day 3.OutcomesAssessed on days 2, 3, 4, 8, 15, 22, 29, 36, and 43. 1. Clinical recurrence. 2. Parasitemia prevalence. 3. Parasite density. 4. Fever resolution. 5. Prevalence of gametocytes. 6. Density of gametocytes. 7. Adverse effects.Notes***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskSeems to be alternate allocation following order of arrival (\"segun el orden de llegada\").Allocation concealment (selection bias)Unclear riskNot clear.Incomplete outcome data (attrition bias) All outcomesLow riskNo dropouts noted.Selective reporting (reporting bias)Low riskNo evidence of bias.Other biasLow riskNo suggestion of other bias.Blinding of participants and personnel (performance bias) All outcomesHigh riskDoes not seem to be blinded (\"con determination no ciega del efecto en grupos iguales\").Blinding of outcome assessment (detection bias) All outcomesHigh risk Wang 2006MethodsIndividually RCTParticipantsNumber of participants: 214 (no dropouts mentioned) Gabon International Tropical Medicine Institute Age range: 6-60, All have *P. falciparum* malaria clinical symptoms and blood smear positive. 1. Trial group: 108, male 50, female 58, age 16.4 +/-10.5 2. Control group: 106, male 52, female 54, age 18.2 +/- 9.4 Exclusion criteria: N/AInterventions1. Artesunate IM injection, daily for 5 days, 1.2 mg/kg each dose, first dose double. PQ 3 tablets (base 7.5 mg/tablet, children use half) once a day, for 5 days. 2. Only artesunate IM injection daily for 5 days, 1.2 mg/kg each dose, the first dose double total 5 days.Outcomes1. Fever clearance time: (hrs) below 37°C continuously measured four times 2. Clinical cure rate at day 7 3. Adverse events (not specified) 4. Recrudescence rate: symptoms appeared again after clinical cure; parasite appeared in blood smear by 28 days Follow-up: 28 daysNotes***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskStated to be randomized, and the fact that numbers per group are not equal supports this contention.Allocation concealment (selection bias)Unclear riskNo information given.Incomplete outcome data (attrition bias) All outcomesUnclear riskNot stated.Selective reporting (reporting bias)Unclear riskNot stated.Other biasUnclear riskUnknown.Blinding of participants and personnel (performance bias) All outcomesUnclear riskNot stated to be blinded.Blinding of outcome assessment (detection bias) All outcomesUnclear riskNot stated to be blinded.[^27][^28][^29][^30][^31][^32][^33][^34][^35][^36][^37][^38][^39][^40]

Characteristics of excluded studies *\[ordered by study ID\]*
-------------------------------------------------------------

StudyReason for exclusionBaird 2002Outcome is cure of asexual infection. No gametocyte outcomes.Barber 1929Not a RCT or quasi-RCT. No controls.Barber 1932MDA with PQ; no other drug.[@b25]Participants were not infected. Safety only trial.Bunnag 1980Comparison of SP plus either five day PQ 15 mg, single dose PQ 30 mg or single dose PQ 45 mg in patients with and without gametocytes at presentation. No regimen without PQ. Not a RCT or quasi-RCT. Authors state they will do further studies, including transmission. No difference in gametocyte outcomes between regimens, and gametocytes persisted for up to 21 days.Burgess 1961Comparison of 15 mg, 30 mg and 45 mg dose of PQ. Outcomes were gametocyte prevalence, density, percent of mosquitoes infected and mean oocysts per mosquito up to eight days. Not a RCT or quasi-RCT. No other drug. Although this trial used different doses by group (12 participants total), they were assigned to participants based on age or body size, and therefore it was not a valid comparison of different doses.Cai 1985Not a RCT.Carter 2011No 8AQ in trial.Che 1987No mention of randomization. No valid comparison group (pyronaridine phosphate plus sulfadoxine plus PQ versus pyronaridine phosphate only).Che 1990No appropriate control group.[@b33]In vitro studies only. Not a RCT.Clyde 1962All patients got PQ.Clyde 1970Individual before-and-after but small number of patients and not controlledClyde 1971Individual before-and-after but small number of patients and not controlledda Silva 1984Trial of treatment regimens, some including PQ, for *P. vivax* and *P. falciparum.*Degowin 1966No 8AQ in trial.Doi 1989Community observational study. Except for a small pilot study, everyone in the intervention villages got PQ. There no \'before\' data from these villages. In the control site, some children received treatment.Giao 2004No appropriate control group (trial of CV8 (contains PQ) versus atovaquone-proguanil)Gogtay 1999Compares QN+PQ against QN+bulaquine. Not a relevant comparison.Gunders 1961Before-and-after studies of gametocytes and mosquito feeds on people with gametocytes given pyrimethamine and PQ in doses ranging from 10 mg to 40 mg base. No group without other drug.Hii 1987Controlled before-and-after study comparing SP+PQ+ITN versus SP+PQ only. Only one cluster per arm and no group without PQ.Huang 1993Not a RCT. Unbalanced groups.Huang 1996PQ given to both intervention groups in same regimen. Malaria treatment regimen was varied (low and higher dose pyronardine/SP).Huang 2001No gametocyte outcomes.Jeffery 1956Non-randomized comparison of gametocytes and infectivity of artificially infected patients treated with CQ or CQ+PQ.Jeffery 1963Observational study of gametocytes and infectivity of two patients given PQ.Jerace 1933Case series studying gametocytes and infectivity of patients given PQ.Kaneko 1989Non-randomized community trial comparing SP+PQ in one village with SP only in another. Only one cluster per arm. The trial was predominantly mass fever test and treat but 75% of people in the intervention village were treated versus 18% in the control village.Karbwang 1991Not randomized, no gametocyte outcomes.Karbwang 1992Pharmacokinetic study; no gametocyte outcomes or control group.Kyaw 1994No control group. All patients got PQ.Li 2007No gametocyte outcomes.Li 2010No gametocyte outcomes.Lin 2004All patients got PQ.Mackerras 1949No other malaria treatment; one patient fed on before and after PQ.Rieckmann 1968Two patients given 45 mg PQ only and fed on by mosquitoes before and after. No other malaria treatment or control group.Rieckmann 196918 patients given CQ alone (N = 2), CQ plus 45 mg PQ (N = 3), or PQ alone in doses ranging from 15 to 45 mg, at either single dose or at one to two week intervals, and fed on before and after one of the doses of PQ. Non-randomized or quasi-randomized.Santana 2007Study of 14 day regimen of 15 mg PQ. Some *P. falciparum* cases were included but study did not distinguish between the patients with *P. falciparum* and *P. vivax*. Study was a comparison of association between methaemoglobinaemia after 14 day PQ in people with and without G6PD deficiency.Shah 2013Review of 21 trials from national drug resistance monitoring system of India. Compares 9 sites where AS+SP+PQ was used with 12 sites where it was not.Shekalaghe 2010Randomized comparison of anaemia after SP+AS+PQ versus placebo. Children with haemoglobin \< 8 g were excluded from receiving PQ.Shekalaghe 2011Trial was a comparison of SP+AS+PQ versus placebo. No comparison of groups with and without PQ.Sun 2011Artesunate + PQ versus Quinimax only. No appropriate control group.Suputtamongkol 2003Comparison of MQ+AS versus MQ + PQ. No appropriate control group.Tangpukdee 2008Comparison of Artequick (contains PQ) with MQ+AS. No appropriate control group and no gametocyte outcomes.Yang 1989All patients got PQ, though different doses of PQ and other malaria treatments.Yeramian 2005PQ given only to *P. vivax* patients for 14 days.Young 1959No other malaria treatment; case series of PQ given daily, bi weekly or weekly to Pf patients.

Characteristics of studies awaiting assessment *\[ordered by study ID\]*
------------------------------------------------------------------------

Chen 1993bMethodsParticipantsInterventionsOutcomesNotesStudy not yet located Ishii 2009MethodsUnclearParticipantsResidents of trial villages in Solomon Islands (number not given)InterventionsTesting of clinical malaria patients for G6PD and addition of single dose PQ to other malaria treatment if appropriateOutcomesVillage prevalence of malariaNotes Li 2006MethodsParticipantsInterventionsOutcomesNotesStudy not yet located

Characteristics of ongoing studies *\[ordered by study ID\]*
------------------------------------------------------------

D\'Alessandro ongoingTrial name or titlePrimaquine\'s Gametocytocidal Efficacy in Malaria Asymptomatic Carriers Treated With Dihydroartemisinin-piperaquine in The GambiaMethodsRandomized, open labelParticipants1200 participants will be recruited Inclusion criteria: • Age ≥ 1 year •Weight = 10 kg • *P. falciparum* mono-infection, density of at least 20 parasites/μL • Axillary temperature \< 37.5ºC • Resident in the trial area and willingness to reside for the duration of the trial • Written informed consent (plus an assent in children = 12 years of age) Exclusion criteria: • G6PD deficiency haemoglobin \< 8 g/dL • Known allergy to any of the trial medications • Known pregnancy or breastfeeding • Clear/documented history of anti-malarial treatment two weeks before contact with trial team • History of blood transfusion in the previous three months • Any chronic or acute conditions that might interfere with the trial as judged by the research clinician • History of sickle cell anaemiaInterventions1. Control: complete course of DHA-PPQ (Eurartesim) 2. Experimental: DHA-PPQ plus single dose PQ at 0.75 mg/kg body weight 3. Experimental: DHA-PPQ plus single dose PQ at 0.4 mg base/kg body weight 4. Experimental: DHA-PPQ plus single dose PQ at 0.2 mg base/kg body weightOutcomesPrimary: Prevalence of *P. falciparum* gametocyte carriers (QT-NASBA) (time frame: Day 7) Secondary: 1. Prevalence of *P. falciparum* gametocytes carriers on days 3, 10, 14, 28 and 42 as determined by QT-NASBA 2. Proportion of individuals infectious to mosquitoes (DMFA) on day 7, with direct membrane feeding assay 3. Haemoglobin change from day 0 on days 3, 7, 10, 14, 21, 28, 35 and 42, as mean (±SD) difference in haemoglobin measured between baseline (day 0) and each follow-up visit day by trial arm 4. Prevalence of infection (asexual stages) on day 3 5. Proportion of participants with recurrent infection (PCR adjusted and unadjusted) from day 7 to day 42 6. Occurrence of adverse events and serious adverse eventsStarting dateAugust 2013; December 2014 (final data collection date for primary outcome measure)Contact information<udalessandro@mrc.gm> +220-4495442-6 ext 4001 <jokebe@mrc.gm> +220-4495442-6 ext 4009 (Joseph Okebe)Notes Gosling ongoingTrial name or titlePhase 2a Dose Escalation Study of the Efficacy, Safety, and Pharmacokinetics of Low Dose Primaquine for Gametocytocidal Activity Against *P. Falciparum* in Sub-Saharan Africa and South East AsiaMethodsRandomized, single blind (outcomes assessor blinded)Participants50 participants being recruited Inclusion criteria: • Male Age ≥ 18 years and \< 50 years • Malaria blood thick film positive • Presence of gametocytes on thick blood film • Agrees to admission to trial ward for 26 hours post diagnosis and available for follow-up visits • No allergies to trial drugs • Hemoglobin ≥ 8 g/dL • No evidence of severe or chronic disease • Written, informed consentInterventionsGroup 1: Active comparator: dihydroartemisinin-piperaquine (DP) only Group 2: Experimental: DP and 0.125 mg/kg PQ Group 3: Experimental: DP and 0.5 mg/kg PQOutcomesPrimary: mosquito infectivity assessed through membrane feeding (time frame: 7 days) Secondary: 1. Gametocyte prevalence and density, hours 2, 6, 12, and 24, days 2, 3, 7, 14, and 28 2. PQ pharmacokinetics - AUC of parent drug and metabolite, hours 1, 2, 3, 4, 6, 8, 12, and 24 3. Asexual parasite prevalence and density baseline, hours 2, 6, 12, and 24, days 2, 3, 7, 14, and 28 4. Safety measurements including haemoglobin and signs of haemolysis baseline, days 1, 2, 3, 7, and 14Starting dateSeptember 2014 (final data collection date for primary outcome measure)Contact information<goslingr@globalhealth.ucsf.edu> 415 597 8114NotesSites in Mali and Thailand Indonesia ongoingTrial name or titleSurveillance and Treatment With Dihydroartemisinin-piperaquine Plus Primaquine (MTC Belu) Sub-title: Impact of Mass Screening and Selective Treatment With Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in High Endemic Area, Belu Regency, Nusa Tenggara Timur Province, Indonesia: a Randomized Cluster TrialMethodsAllocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment Cluster randomized.ParticipantsTarget sample size: 1488 participants Inclusion criteria: • All villagers of the all selected clusters Exclusion criteria: • Pregnant women during their first trimester • Single dose PQ should not be given for infants under one year-old, pregnant women in all trimesters of pregnancy, breast-feeding mother and patients with G6PD deficiency Age minimum: N/AAge maximum: N/AGender: BothInterventionsDrug: dihydroartemisinin-piperaquine Drug: PQ (1) intervention arm of mass screening and treatment with interval of 6 weeks; (2) intervention arm of mass screening and treatment with interval of three months; and (3) control arm without mass screening and treatment. The intervention arm with six weeks interval represents a new proposed method to detection malaria infections, while the intervention arm with three month interval represents the Ministry of Health current policy of active case detection in Indonesia, and the third arm will serve as the control for Ministry of Health\'s policy. No arm without PQOutcomesMalaria incidence (time frame: six months) Anemia (time frame: six months)Starting dateJune 2013Contact informationIndonesia University/ Walter and Eliza Hall Institute of Medical ResearchNotes<http://clinicaltrials.gov/show/NCT01878357> Stated to be completed Saunders ongoingTrial name or titleActive Surveillance for *P. falciparum* Drug Resistance With Assessment of Transmission Blocking Activity of Single Dose Primaquine in CambodiaMethodsRandomized, open labelParticipants150 male and female participants Inclusion criteria: 1. Volunteer with uncomplicated *P. falciparum* malaria (volunteers with mixed *P. falciparum* and *P. vivax* infections may be enrolled), 18 to 65 years of age 2. Baseline asexual parasite density between 1000 to 200,000 parasites/µL 3. Able to provide informed consent 4. Available and agree to follow-up for anticipated trial duration including three day treatment course at the MTF and weekly follow-up for the 42-day period 5. Authorized by local commander to participate if active duty military Exclusion criteria: 1. Allergic reaction or contraindication to DHA, piperaquine or PQ 2. Significant acute comorbidity requiring urgent medical intervention 3. Signs or symptoms and parasitological confirmation of severe malaria 4. Use of any antimalarial within the past 14 days. 5. Class I or II G6PD deficiency (defined as severe) as determined at screening 6. Pregnant or lactating female, or female of childbearing age, up to 50 years of age, who does not agree to use an acceptable form of contraception during the trial 7. Clinically significant abnormal EKG, including a QTcF interval \> 500 ms at enrolment. 8. Known or suspected concomitant use of QTc prolonging medications. 9. Judged by the investigator to be otherwise unsuitable for trial participationInterventionsGroup 1: DHA-piperaquine 3-day course plus 45 mg single dose PQ Group 2: DHA-piperaquine 3-day course of DHA-piperaquineOutcomesPrimary: Efficacy rates at 42 days for DP with and without single dose PQ for uncomplicated *P. falciparum* diagnosed by positive PCR-corrected malaria microscopy Secondary: Efficacy of PQ to treat sexual stage gametocyte infection and prevent transmission of *P. falciparum* gametocytes to mosquitoes.Starting dateDecember 2012; December 2014 (final data collection date for primary outcome measure)Contact informationDavid Saunders, MD, MPH 66-2-696-2798 <david.saunders@afrims.org> Chanthap Lon, MD, MCTM 855 23 881 845 <chanthapl@afrims.org>Notes Shekalaghe ongoingTrial name or titleThe Optimal Timing of Primaquine to Prevent Malaria Transmission After Artemisinin-Combination TherapyMethodsRandomized, open labelParticipants250 male and female participants Inclusion criteria: • Age three years to 17 years • Residents of research area • Willingness to come for complete scheduled follow-up • Uncomplicated malaria with *P. falciparum* mono-infection • Axillary temperature = 37.5°C and \< 39.5°C, or history of fever in previous 48 hours • No history of adverse reactions to trial medication • Understanding of the trial procedures by parent or guardian and willing to participate by signing written informed consent forms Exclusion criteria: • Haemoglobin below 9 g/dL • Inability to take drugs orally • Known hypersensitivity to any of the drugs given • Reported treatment with antimalarial chemotherapy in the past two weeks • Evidence of chronic disease or acute infection other than malaria • Domicile outside the trial area • Signs of severe malaria (such as respiratory distress, altered consciousness deep breathing, anaemia) • Participating in other malaria studies conducted in the region • Mixed malaria parasite species infection • Positive pregnant test by urine (UPT) if participant is female aged above 12 years • G6PD deficient using the fluorescence spot testInterventionsGroup 1: Artemether lumefantrine (AL) 6 dose regime orally Group 2: AL 6 dose regime plus single dose PQ (0.75/kg) on day 0 Group 3: AL 6 dose regimen plus single dose PQ (0.75/kg) on day 2OutcomesPrimary: Gametocyte prevalence and density by microscopy and QT-NASBA on day 14 Secondary: • Haemoglobin level on days 3, 7, 10 and 14 • Proportion of infected mosquitoes on day 7 after initiation of treatment and the intensity of infection (oocyst burden) by membrane feeding assayStarting dateMay 2013; October 2013 (final data collection date for primary outcome measure)Contact informationSeif Shekalaghe, MD, PhD <sshekalaghe@ihi.or.tz> +255 755 470472NotesClinicalTrials.gov NCT019067889. Tanzania KCMC and Ifakara Thailand PharmacokineticTrial name or titlePharmacokinetic Study of Primaquine and Dihydroartemisinin-Piperaquine in Healthy SubjectsMethodsPhase 1 Randomized, crossover, open label safety/efficacy study. Primary purpose: treatmentParticipantsInclusion criteria: 1. Healthy as judged by a responsible physician with no abnormality identified on a medical evaluation including medical history and physical examination. 2. Male and female non-smokers aged between 18 years to 60 years. 3. Males and females weight between 36 to 75 kilograms. 4. A female is eligible to enter and participate in this study if she is: of non-childbearing potential including pre-menopausal females with documented (medical report verification) hysterectomy or double oophorectomy; or postmenopausal defined as 12 months of spontaneous amenorrhoea or 6 months of spontaneous amenorrhoea with serum follicle stimulating hormone levels = 40 mIU/mL or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy; or of childbearing potential, has a negative serum pregnancy test at screening and prior to start the study drug in each period, and abstain from sexual intercourse or agrees to using effective contraceptive methods (for example, intrauterine device, hormonal contraceptive drug, tubal ligation or female barrier method with spermicide) during the study until completion of the follow-up procedures. 5. A male is eligible to enter and participate in this study if he: agrees to abstain from (or use a condom during) sexual intercourse with females of childbearing potential or lactating females; or is willing to use a condom/spermicide, during the study until completion of the follow-up procedures. 6. Provide a signed and dated written informed consent prior to study participation. 7. Normal electrocardiogram (ECG) with QTc \< 450 msec. 8. Willingness and ability to comply with the study protocol for the duration of the trial. Exclusion criteria: 1. Females who are pregnant, trying to get pregnant, or are lactating. 2. The subject has evidence of active substance abuse that may compromise safety, pharmacokinetics, or ability to adhere with protocol instructions. 3. A positive pre-study hepatitis B surface antigen, positive hepatitis C antibody, or positive human immunodeficiency virus-1 (HIV-1) antibody result at screening. 4. Subjects with a personal history of cardiac disease, symptomatic or asymptomatic arrhythmias, syncopal episodes, or additional risk factors for torsades de points (heart failure, hypokalaemia) or with a family history of sudden cardiac death. 5. A creatinine clearance \< 70 mL/min as determined by Cockcroft-Gault equation: CLcr (mL/min) = (140 - age) \* Wt / (72 \* Scr) (multiply answer by 0.85 for females) where age is in years, weight (wt) is in kg, and serum creatinine (Scr) is in units of mg/dL (Cockroft [@b87]). 6. History of alcohol or substance abuse or dependence within six months of the study. 7. Use of prescription or non-prescription drugs except paracetamol at doses of up to 2 g/day, including vitamins, herbal and dietary supplements (including St. John\'s Wort) within seven days (or 14 days if the drug is a potential enzyme inducer) or five times the drug half-life (whichever is longer) prior to the first dose of study medication until the completion of the follow-up procedure, unless in the opinion of investigator, the medication will not interfere with the study procedures or compromise subject safety; the investigator will take advice from the manufacturer representative as necessary. 8. The subject has participated in a clinical trial and has received a drug or a new chemical entity within 30 days, or five half-lives, or twice the duration of the biological effect of any drug (whichever is longer) prior to the first dose of study medication. 9. The subject is unwilling to abstain from ingesting alcohol within 48 hours prior to the first dose of study medication until collection of the final pharmacokinetic sample during each regimen. 10. Subjects who have donated blood to the extent that participation in the study would result in more than 300 mL blood donated within a 30-day period. Note: This does not include plasma donation. 11. Subjects who have a history of allergy to the study drug or drugs of this class, or a history of drug or other allergy that, in the opinion of the investigator, contraindicates participation in the trial. In addition, if heparin is used during pharmacokinetic sampling, subjects with a history of sensitivity to heparin or heparin-induced thrombocytopenia should not be enrolled. 12. Lack of suitability for participation in this study, including but not limited to, unstable medical conditions, systemic disease manifested by tendency to granulocytopenia for example rheumatoid arthritis and lupus erythematosus that in the opinion of the investigator would compromise their participation in the trial. 13. AST or ALT = 1.5 upper limit of normal (ULN). 14. Subjects with history of renal disease, hepatic disease or cholecystectomy or both. 15. G6PD deficient detected by Beutler\'s dye test. 16. Abnormal methaemoglobin level. 17. History of antimalarial drugs use including but not limited to MQ, chloroquine, PQ, artesunate, piperaquine and pyronaridine treatment within 12months. 18. Subject who received quinacrine in last 30 days.InterventionsThis study is planned to evaluate potential pharmacokinetic interaction of orally administered PQ and dihydroartemisinin-piperaquine (DHA-PQP) in healthy adult subjects. The results of these interaction studies are important in order to provide clinical guidance for the optimum combination of PQ and DHA-PQP treatment regimens in malaria infections.OutcomesPrimary \* AUC for PQ (Time frame: 36 days; designated as safety issue: no) Area under the concentration-time curve \[(AUC(0-∞) and AUC(0-last)\] and maximal concentration (C~max~) for PQ and metabolites when given alone or together with DHA-PQP. \* AUC for dihydroartemisinin (DHA) and piperaquine (PQP) (Time frame: 36 days; designated as safety issue: no) Area under the concentration-time curve \[(AUC(0-∞) and AUC(0-last)\] and maximal concentration (C~max~) for piperaquine and dihydroartemisinin when given alone as DHA-PQP or together with PQ. Secondary Clearance rate and half life of PQ and its metabolites (Time frame: 36 days; designated as safety issue: no) PQ, carboxyprimaquine (and other detectable major metabolites) elimination clearance rate (CL/F), terminal elimination half-life (t~1/2~) and apparent volume of distribution (Vd) Dihydroartemisinin and piperaquine elimination clearance rate (CL/F), terminal elimination half-life (t~1/2~) and apparent volume of distribution (Vd).Safety of dihydroartemisinin-piperaquine (DHA-PQP) (Time frame: 36 days; designated as safety issue: yes) Safety and tolerability parameters, including adverse events, clinical laboratory, and vital signs assessments, in particular QTc prolongation for DHA-PQPPharmacogenetic polymorphisms (Time frame: 36 days; designated as safety issue: yes) in the case of unusually high or low drug levels.Starting dateFebruary 2012Contact informationSasithon Pukrittayakamee, MD, Principal Investigator, Mahidol University Salwaluk Panapipat, MBA <salwaluk@tropmedres.ac>NotesNCT01525511 University of Oxford Tiono ongoingTrial name or titleLow Dose Primaquine for Clearance of Gametocytes: LOPRIM-1MethodsRandomized, parallel assignment, double blind (subject, caregiver, investigator, outcomes assessor); safety/efficacy studyParticipantsTarget sample size 360 participants Inclusion criteria • Age = 2 and \<15 years • *P. falciparum* parasitaemia = 1000 and \< 200,000 parasites/µL • *P. falciparum* gametocytes • Normal G6PD • Informed consent by legally acceptable representative Exclusion criteria • Enrolled in another study • Fever or history of fever in last 24 hours • Evidence of severe illness/danger signs • Known allergy to study medications • Hb \< 8 g/dL • Started menstruation • Pregnancy or breastfeeding • Antimalarials taken within last 2 days • PQ taken within last 4 weeks • Blood transfusion within the last 90 days • Non-falciparum malaria co-infectionInterventionsGroup 1: Artemether lumefantrine Group 2: Artemether lumefantrine with a single dose of 0.25 mg/kg PQ Group 3: Artemether lumefantrine with a single dose of 0.4 mg/kg PQOutcomesPrimary: gametocyte carriage (time frame: 14 days during follow-up) Secondary: • haematological recovery (time frame: 14 days during follow-up) • transmission to *An. gambiae* mosquitoes (time frame: day 3, 7, 10 and 14)Starting dateSeptember 2013Contact information<t.alfred@fasonet.bf>; <teun.bousema@lshtm.ac.uk>NotesBurkina Faso, Centre international de recherche et de formation sur le paludisme. Ougadougou. clinicaltrials.gov NCT01935882

DATA AND ANALYSES
=================

Comparison 1.Non-artemisinin treatment regimen: PQ versus no PQOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Participants with gametocytes6Risk Ratio (M-H, Fixed, 95% CI)Subtotals only 1.1 Day 2296Risk Ratio (M-H, Fixed, 95% CI)0.72 \[0.46, 1.12\] 1.2 Day 3183Risk Ratio (M-H, Fixed, 95% CI)0.75 \[0.45, 1.27\] 1.3 Day 4 or 53273Risk Ratio (M-H, Fixed, 95% CI)0.84 \[0.64, 1.09\] 1.4 Day 86498Risk Ratio (M-H, Fixed, 95% CI)0.60 \[0.50, 0.73\] 1.5 Day 154366Risk Ratio (M-H, Fixed, 95% CI)0.31 \[0.22, 0.43\] 1.6 Day 224323Risk Ratio (M-H, Fixed, 95% CI)0.30 \[0.20, 0.46\] 1.7 Day 294290Risk Ratio (M-H, Fixed, 95% CI)0.34 \[0.19, 0.60\] 1.8 Day 36181Risk Ratio (M-H, Fixed, 95% CI)0.37 \[0.15, 0.94\] 1.9 Day 43173Risk Ratio (M-H, Fixed, 95% CI)0.27 \[0.04, 1.71\]2 Gametocyte clearance time (days)1Mean Difference (IV, Fixed, 95% CI)Totals not selected3 Participants infectious2Risk Ratio (M-H, Fixed, 95% CI)Subtotals only 3.1 Day 5230Risk Ratio (M-H, Fixed, 95% CI)0.06 \[0.01, 0.42\] 3.2 Day 8230Risk Ratio (M-H, Fixed, 95% CI)0.07 \[0.01, 0.45\] 3.3 Day 15230Risk Ratio (M-H, Fixed, 95% CI)0.14 \[0.02, 1.04\] 3.4 Day 22230Risk Ratio (M-H, Fixed, 95% CI)0.33 \[0.02, 7.24\]4 Mosquitoes infected1Risk Ratio (M-H, Fixed, 95% CI)Totals not selected 4.1 Day 51Risk Ratio (M-H, Fixed, 95% CI)0.0 \[0.0, 0.0\] 4.2 Day 81Risk Ratio (M-H, Fixed, 95% CI)0.0 \[0.0, 0.0\] 4.3 Day 151Risk Ratio (M-H, Fixed, 95% CI)0.0 \[0.0, 0.0\] 4.4 Day 221Risk Ratio (M-H, Fixed, 95% CI)0.0 \[0.0, 0.0\]5 Participants with asexual parasites at day 291Risk Ratio (M-H, Fixed, 95% CI)Subtotals only 5.1 Not PCR adjusted1209Risk Ratio (M-H, Fixed, 95% CI)0.94 \[0.78, 1.15\] 5.2 PCR adjusted1209Risk Ratio (M-H, Fixed, 95% CI)0.92 \[0.69, 1.23\]6 Asexual parasite clearance time (hrs)2144Mean Difference (IV, Fixed, 95% CI)-1.68 \[-9.60, 6.25\]7 Adverse effects1Risk Ratio (M-H, Fixed, 95% CI)Totals not selected 7.1 Nausea1Risk Ratio (M-H, Fixed, 95% CI)0.0 \[0.0, 0.0\] 7.2 Vomiting1Risk Ratio (M-H, Fixed, 95% CI)0.0 \[0.0, 0.0\] 7.3 Dizziness1Risk Ratio (M-H, Fixed, 95% CI)0.0 \[0.0, 0.0\] 7.4 Any adverse effect1Risk Ratio (M-H, Fixed, 95% CI)0.0 \[0.0, 0.0\]8 By dose: Participants with gametocytes at day 8 (microscopy)6Risk Ratio (M-H, Fixed, 95% CI)Subtotals only 8.1 \<0.4 mg/kg PQ per day159Risk Ratio (M-H, Fixed, 95% CI)1.76 \[0.97, 3.18\] 8.2 ≥ 0.4 to \< 0.6 mg/kg PQ per day2283Risk Ratio (M-H, Fixed, 95% CI)0.62 \[0.50, 0.76\] 8.3 ≥ 0.6 mg/kg PQ per day4186Risk Ratio (M-H, Fixed, 95% CI)0.39 \[0.25, 0.62\]9 By schedule: Participants with gametocytes at day 86Risk Ratio (M-H, Fixed, 95% CI)Subtotals only 9.1 Single dose day 1 or 24191Risk Ratio (M-H, Fixed, 95% CI)0.64 \[0.49, 0.84\] 9.2 Single dose day 3 or 43243Risk Ratio (M-H, Fixed, 95% CI)0.45 \[0.33, 0.60\] 9.3 Multiple dose days 1 to 7196Risk Ratio (M-H, Fixed, 95% CI)1.22 \[0.69, 2.18\]

Comparison 2.Artemisinin treatment regimen: PQ versus no PQOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Participants with gametocytes (microscopy)6Risk Ratio (M-H, Random, 95% CI)Subtotals only 1.1 Day 44971Risk Ratio (M-H, Random, 95% CI)1.00 \[0.95, 1.05\] 1.2 Day 861121Risk Ratio (M-H, Random, 95% CI)0.24 \[0.10, 0.55\] 1.3 Day 154995Risk Ratio (M-H, Random, 95% CI)0.09 \[0.04, 0.19\] 1.4 Day 223858Risk Ratio (M-H, Random, 95% CI)0.10 \[0.03, 0.32\] 1.5 Day 294945Risk Ratio (M-H, Random, 95% CI)0.17 \[0.04, 0.72\] 1.6 Day 363838Risk Ratio (M-H, Random, 95% CI)0.21 \[0.01, 4.32\] 1.7 Day 434917Risk Ratio (M-H, Random, 95% CI)0.41 \[0.04, 3.89\]2 Participants with gametocytes (PCR)3Risk Ratio (M-H, Random, 95% CI)Subtotals only 2.1 Day 83627Risk Ratio (M-H, Random, 95% CI)0.42 \[0.26, 0.69\] 2.2 Day 153609Risk Ratio (M-H, Random, 95% CI)0.27 \[0.11, 0.70\] 2.3 Day 29190Risk Ratio (M-H, Random, 95% CI)0.23 \[0.08, 0.62\] 2.4 Day 43179Risk Ratio (M-H, Random, 95% CI)0.44 \[0.17, 1.16\]3 Participants with asexual parasites5Risk Ratio (M-H, Fixed, 95% CI)Subtotals only 3.1 Day 8194Risk Ratio (M-H, Fixed, 95% CI)1.28 \[0.30, 5.40\] 3.2 Day 152198Risk Ratio (M-H, Fixed, 95% CI)0.97 \[0.23, 4.15\] 3.3 Day 293747Risk Ratio (M-H, Fixed, 95% CI)0.54 \[0.33, 0.88\] 3.4 Day 432178Risk Ratio (M-H, Fixed, 95% CI)1.03 \[0.59, 1.81\]4 Asexual parasite clearance time (hrs)150Mean Difference (IV, Fixed, 95% CI)-6.0 \[-16.31, 4.31\]5 Haemoglobin concentration1Mean Difference (IV, Fixed, 95% CI)Totals not selected 5.1 Day 81Mean Difference (IV, Fixed, 95% CI)0.0 \[0.0, 0.0\] 5.2 Day 151Mean Difference (IV, Fixed, 95% CI)0.0 \[0.0, 0.0\] 5.3 Day 291Mean Difference (IV, Fixed, 95% CI)0.0 \[0.0, 0.0\] 5.4 Day 431Mean Difference (IV, Fixed, 95% CI)0.0 \[0.0, 0.0\]6 % change in haemoglobin concentration1Mean Difference (IV, Fixed, 95% CI)Totals not selected 6.1 Day 81Mean Difference (IV, Fixed, 95% CI)0.0 \[0.0, 0.0\] 6.2 Day 151Mean Difference (IV, Fixed, 95% CI)0.0 \[0.0, 0.0\] 6.3 Day 291Mean Difference (IV, Fixed, 95% CI)0.0 \[0.0, 0.0\] 6.4 Day 431Mean Difference (IV, Fixed, 95% CI)0.0 \[0.0, 0.0\]7 Other adverse effects2Risk Ratio (M-H, Fixed, 95% CI)Totals not selected 7.1 Headache1Risk Ratio (M-H, Fixed, 95% CI)0.0 \[0.0, 0.0\] 7.2 Fatigue1Risk Ratio (M-H, Fixed, 95% CI)0.0 \[0.0, 0.0\] 7.3 Nausea1Risk Ratio (M-H, Fixed, 95% CI)0.0 \[0.0, 0.0\] 7.4 Vomiting1Risk Ratio (M-H, Fixed, 95% CI)0.0 \[0.0, 0.0\] 7.5 Abdominal pain1Risk Ratio (M-H, Fixed, 95% CI)0.0 \[0.0, 0.0\] 7.6 Diarrhea1Risk Ratio (M-H, Fixed, 95% CI)0.0 \[0.0, 0.0\] 7.7 Pruritis1Risk Ratio (M-H, Fixed, 95% CI)0.0 \[0.0, 0.0\] 7.8 Paresthesia1Risk Ratio (M-H, Fixed, 95% CI)0.0 \[0.0, 0.0\] 7.9 Unspecified1Risk Ratio (M-H, Fixed, 95% CI)0.0 \[0.0, 0.0\]8 By dose: Participants with gametocytes at day 8 (microscopy or PCR)8Risk Ratio (M-H, Fixed, 95% CI)Subtotals only 8.1 \< 0.4 mg/kg PQ per day1223Risk Ratio (M-H, Fixed, 95% CI)0.67 \[0.44, 1.02\] 8.2 ≥ 0.4 to \< 0.6 mg/kg PQ per day2269Risk Ratio (M-H, Fixed, 95% CI)0.34 \[0.19, 0.59\] 8.3 ≥ 0.6 mg/kg PQ per day71380Risk Ratio (M-H, Fixed, 95% CI)0.29 \[0.22, 0.37\]9 By schedule: Participants with gametocytes at day 8 (microscopy or PCR)8Risk Ratio (M-H, Fixed, 95% CI)Subtotals only 9.1 Single dose day 1 or 22843Risk Ratio (M-H, Fixed, 95% CI)0.13 \[0.07, 0.22\] 9.2 Single dose day 3 or 45748Risk Ratio (M-H, Fixed, 95% CI)0.47 \[0.37, 0.59\] 9.3 Multiple dose days 1 to 7150Risk Ratio (M-H, Fixed, 95% CI)0.64 \[0.16, 2.56\]

Comparison 3.PQ versus no PQ; gametocytes at day 8 (microscopy or PCR); stratified by non-artemisinin versus artemisinin regimenOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Participants with gametocytes at day 8 (microscopy or PCR)122141Risk Ratio (M-H, Random, 95% CI)0.43 \[0.32, 0.58\] 1.1 Non-artemisinin-based partner drug6499Risk Ratio (M-H, Random, 95% CI)0.63 \[0.44, 0.88\] 1.2 Artemisinin-based partner drug81642Risk Ratio (M-H, Random, 95% CI)0.33 \[0.21, 0.52\]

Comparison 4.PQ versus other 8AQOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Participants with gametocytes on day 82112Risk Ratio (M-H, Fixed, 95% CI)0.41 \[0.26, 0.66\]

What\'s new
===========

Last assessed as up-to-date: 10 February 2014.

DateEventDescription24 June 2014New citation required and conclusions have changedWe conducted a new search and added new studies. We stratified the analysis by dose of primaquine.24 June 2014New search has been performedWe stratified the analysis by dose or primaquine and added new studies. We clarified the excluded studies.

![Comparison 1 Non-artemisinin treatment regimen: PQ versus no PQ, Outcome 1 Participants with gametocytes.](CD008152-0001-f5){#d36e14161}

![Comparison 1 Non-artemisinin treatment regimen: PQ versus no PQ, Outcome 2 Gametocyte clearance time (days).](CD008152-0001-f6){#d36e14168}

![Comparison 1 Non-artemisinin treatment regimen: PQ versus no PQ, Outcome 3 Participants infectious.](CD008152-0001-f7){#d36e14175}

![Comparison 1 Non-artemisinin treatment regimen: PQ versus no PQ, Outcome 4 Mosquitoes infected.](CD008152-0001-f8){#d36e14182}

![Comparison 1 Non-artemisinin treatment regimen: PQ versus no PQ, Outcome 5 Participants with asexual parasites at day 29.](CD008152-0001-f9){#d36e14189}

![Comparison 1 Non-artemisinin treatment regimen: PQ versus no PQ, Outcome 6 Asexual parasite clearance time (hrs).](CD008152-0001-f10){#d36e14196}

![Comparison 1 Non-artemisinin treatment regimen: PQ versus no PQ, Outcome 7 Adverse effects.](CD008152-0001-f11){#d36e14203}

![Comparison 1 Non-artemisinin treatment regimen: PQ versus no PQ, Outcome 8 By dose: Participants with gametocytes at day 8 (microscopy).](CD008152-0001-f12){#d36e14210}

![Comparison 1 Non-artemisinin treatment regimen: PQ versus no PQ, Outcome 9 By schedule: Participants with gametocytes at day 8.](CD008152-0001-f13){#d36e14218}

![Comparison 2 Artemisinin treatment regimen: PQ versus no PQ, Outcome 1 Participants with gametocytes (microscopy).](CD008152-0001-f14){#d36e14225}

![Comparison 2 Artemisinin treatment regimen: PQ versus no PQ, Outcome 2 Participants with gametocytes (PCR).](CD008152-0001-f15){#d36e14232}

![Comparison 2 Artemisinin treatment regimen: PQ versus no PQ, Outcome 3 Participants with asexual parasites.](CD008152-0001-f16){#d36e14239}

![Comparison 2 Artemisinin treatment regimen: PQ versus no PQ, Outcome 4 Asexual parasite clearance time (hrs).](CD008152-0001-f17){#d36e14246}

![Comparison 2 Artemisinin treatment regimen: PQ versus no PQ, Outcome 5 Haemoglobin concentration.](CD008152-0001-f18){#d36e14253}

![Comparison 2 Artemisinin treatment regimen: PQ versus no PQ, Outcome 6 % change in haemoglobin concentration.](CD008152-0001-f19){#d36e14260}

![Comparison 2 Artemisinin treatment regimen: PQ versus no PQ, Outcome 7 Other adverse effects.](CD008152-0001-f20){#d36e14267}

![Comparison 2 Artemisinin treatment regimen: PQ versus no PQ, Outcome 8 By dose: Participants with gametocytes at day 8 (microscopy or PCR).](CD008152-0001-f21){#d36e14274}

![Comparison 2 Artemisinin treatment regimen: PQ versus no PQ, Outcome 9 By schedule: Participants with gametocytes at day 8 (microscopy or PCR).](CD008152-0001-f22){#d36e14281}

![Comparison 3 PQ versus no PQ; gametocytes at day 8 (microscopy or PCR); stratified by non-artemisinin versus artemisinin regimen, Outcome 1 Participants with gametocytes at day 8 (microscopy or PCR).](CD008152-0001-f23){#d36e14288}

![Comparison 4 PQ versus other 8AQ, Outcome 1 Participants with gametocytes on day 8.](CD008152-0001-f24){#d36e14296}

Contributions of authors
========================

This edition: PMG and HG added the new studies. PG helped rewrite the review. All authors contributed to the interpretation of the results and the conclusions drawn. First edition: Two authors (PMG and HG) independently screened all abstracts, applied inclusion criteria, and extracted data. PG helped structure the review, and contributed to the logic framework of the SOF tables. All authors contributed to the writing of the review, the interpretation of the results and the conclusions drawn.
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Differences between protocol and review
=======================================

1\) After reading the trials, we added several new outcomes and modified some outcomes; we deleted two outcomes. Changes to primary outcomes:

-   Proportion of participants with gametocytes: we added: by microscopy and PCR.

-   We added: Proportion of participants infectious.

-   We included : Gametocyte density (by microscopy and PCR).

-   ADDED: Gametocyte clearance time (also called duration of gametocyte carriage).

We arranged the primary outcomes to capture the three categories: transmission intensity, infectiousness and potential infectiousness. Changes to secondary outcomes:

-   We deleted AUC of asexual parasite density over time. We did not identify any relevant data.

-   We added asexual clearance time.

Changes to Adverse events:

-   We deleted: All adverse events (data reported was minimal and not in a form that was easily summarised. The main question is whether there are serious adverse events).

```{=html}
<!-- -->
```
-   We modified haemolysis or drop in haemoglobin or PCV (as assessed/defined in each trial) by deleting reference to G6PD since these outcomes occur in non-G6PD people too. We also added PCV since this was used in some trials as a measure of anaemia.

2\) In the first version of the review, we deleted the objective: \"To compare the effects of different doses and schedules of PQ given to reduce infectiousness\" and we modified the definition of control in comparisons accordingly. We only included controls without PQ. We deleted the comparison of different doses of PQ with identical other treatment regimens since it does not answer the important question of whether adding PQ is effective. We included one trial with two arms using different doses of PQ with same other treatment regimens as two separate arms within the same comparison. In the update, we reversed this decision. 3) We planned to use the following comparisons described in the protocol:

-   CQ (with and without PQ, or with different doses of PQ)

-   SP (with and without PQ, or with different doses of PQ)

-   CQ plus sulfadoxine + pyrimethamine (with and without PQ, or with different doses of PQ)

-   Artemisinin derivatives (with and without PQ, or with different doses of PQ)

-   Other drugs (with and without PQ, or with different doses of PQ)

In the review, we changed the groups, added some, and combined some for the following reasons: a) some trials combined two types of malaria treatment regimens, not distinguishing the patients who received each one (for example, CQ or CQ plus SP). b) there were many different artemisinin derivatives and combinations tested, with few trials of each, so these were grouped within the same comparison. We also grouped combinations of an artemisinin derivative with SP here. 3) There were no cluster-RCTs so we deleted how we would manage them from the Methods. If we include any cluster-RCTs in future editions, we will check that trials have correctly adjusted for clustering and, if not, attempt to make this adjustment. When the analyses have not adjusted for clustering, we will attempt to adjust the results for clustering by multiplying the standard errors of the estimates by the square root of the design effect, where the design effect is calculated as DEff=1+(m-1)\*ICC. This assumes that the necessary information is reported, the average cluster size (m) and the intra-cluster correlation coefficient (ICC). 4) We intended a sensitivity analysis to investigate the robustness of the results to the quality (risk of bias) components, but were unable to do so as there were insufficient trials. If appropriate and necessary, we will conduct sensitivity analysis on cluster-RCTs using a range of estimates for the ICC to see if clustering could influence the individual trial\'s result.

INDEX TERMS
===========

Medical Subject Headings (MeSH)
-------------------------------

Antimalarials \[\*administration & dosage\]; Artemisinins \[therapeutic use\]; Chloroquine \[therapeutic use\]; Drug Combinations; Glucosephosphate Dehydrogenase Deficiency \[diagnosis\]; Malaria, Falciparum \[\*prevention & control; transmission\]; Mefloquine \[therapeuticuse\]; Plasmodium falciparum \[\*drug effects\]; Primaquine \[\*administration & dosage\]; Pyrimethamine; Quinine \[therapeutic use\]; Randomized Controlled Trials as Topic; Sulfadoxine

MeSH check words
----------------

Humans

[^1]: **Editorial group:** Cochrane Infectious Diseases Group.

[^2]: **Publication status and date:** New search for studies and content updated (conclusions changed), published in Issue 6, 2014.

[^3]: **Review content assessed as up-to-date:** 10 February 2014.

[^4]: ^1^ AUC estimates (log(10)AUC for day 1 to 43) are included as footnotes for each dosing strata.

[^5]: ^2^ No serious risk of bias: Includes one trial with no risk of bias detected.

[^6]: ^3^ Downgraded by 2 for very serious imprecision: One small trial with CIs that include 50% reduction and no effect.

[^7]: ^4^ There was no log(10)AUC day 1 to 43 % reduction data for this dose.Not downgraded on imprecision. Although one trial has few events, effect size is consistent with the second trial.

[^8]: ^6^ Log(10)AUC day 1 to 43 % reduction: 24.3% and 27.1% (one trial, two comparisons).

[^9]: ^7^ Includes seven trials, with 11 comparisons: one trial included five separate comparisons with AS-AQ, DHAP, AS-MQ, and AL (Smithuis [@b15]).

[^10]: ^8^ No serious inconsistency: whilst there is marked quantitative heterogeneity, the studies with no demonstrable effect had few events. Not downgraded.

[^11]: ^9^ Log(10)AUC day 1 to 43 % reduction: range from 21.1% to 87.5%. We included four trials with 12 comparisons. We excluded one trial as high risk of bias (Vasquez [@b17]) due to small sample size and large difference in baseline gametocyte count in the two groups.

[^12]: ^10^ Shekalaghe [@b13] reported relative decrease in haemoglobin against baseline in both groups at day 8, 15, 29 and 43 in all participants irrespective of G6PD status. The comparison between those receiving PQ and those not did not demonstrate a difference at any time point. We presented day 43 in this table.

[^13]: ^11^ Downgraded by 2 for very serious indirectness: the percentage of people with large drops in haemoglobin, not the mean change in the population, is the important safety outcome; and the estimates are averages in a small population (N = 99) that includes people with normal G6PD function so unlikely to detect effects in a small subgroup with a relatively uncommon adverse event.

[^14]: \* first day of any treatment = day 1 i.v. = intravenous injection; i.m. = intramuscular injection; Pf = *P. falciparum*; Pv = *P. vivax*

[^15]: ^1^ High category dose PQ used in both studies = 0.6 mg/kg.

[^16]: ^2^ Downgraded by 1 for serious risk of bias: allocation was not concealed; both experiments were performed by the same author team and the methods were not clear.

[^17]: ^3^ Downgraded by 1 for serious imprecision: the sample size is small (N = 30; downgraded by 2) but the effect is large (upgraded by 1). In the control group, infectivity wanes by day 15.

[^18]: ^4^ Downgraded by 1 for serious risk of bias: trial had methodological deficiencies.

[^19]: ^5^ Downgraded by 1 for serious imprecision: single trial, small sample size, wide CIs.

[^20]: ^6^ Downgraded by 1 for serious indirectness: 7 days of PQ given.

[^21]: ^7^No serious imprecision: although the sample size is limited, the effect is large.

[^22]: ^8^ Log(10)AUC day 1 to 43 % reduction relative decrease: 2 estimates from one trial of 24.3% to 27.1% (N = 219), assessed as moderate quality evidence.

[^23]: ^9^ Data from Khoo [@b9] could not be used because it did not distinguish between patients with *P. falciparum* and *P. vivax* and their respective treatments. There was a much higher risk of adverse haemolytic events in those who received PQ (OR of 22.27 for both haemolysis and need for blood transfusion), but the participants included those receiving a short course (three days) of PQ with those receiving a 14-day regimen. Only individuals with G6PD deficiency were included.

[^24]: ^10^ For the ten included trials, the G6PD status of participants varied: two trials excluded patients with G6PD deficiency trials), one trial included only those with G6PD deficiency, two trials did not screen for G6PD deficiency, and five trials did not report or comment on screening for G6PD status. No trials systematically reported on adverse effects.

[^25]: ^1^Cochrane Infectious Diseases Group Specialized Register.

[^26]: ^2^Search terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration (Lefebvre [@b100]); Upper case: MeSH or EMTREE heading; Lower case: free text term.

[^27]: AL = artemether-lumefantrine

[^28]: AQ = amodiaquine

[^29]: AS = artesunate

[^30]: CQ = chloroquine

[^31]: DHAP = dihydroartemisinin-piperaquine

[^32]: G6PD = glucose-6-phosphate dehydrogenase

[^33]: IM = Intramuscular

[^34]: MQ = mefloquine

[^35]: PCR = polymerase chain reaction

[^36]: Pf = *Plasmodium falciparum*

[^37]: PQ = primaquine

[^38]: QN = quinine

[^39]: RCT = randomized controlled trial

[^40]: SP = sulfadoxine-pyrimethamine
